非小细胞肺癌术后化疗相关基因的临床与基础研究
|
摘要
研究背景
恶性肿瘤是目前危害人类健康最严重疾病之一。近二十年全国性死亡原因调查显示,死亡率上升幅度最大的是肺癌。目前肺癌的治疗一般采用手术、化疗、放疗、免疫治疗等综合措施,其中化疗作为全身性治疗手段,在恶性肿瘤的治疗中具有手术和放疗不能替代的地位。经过长期的临床经验总结和一些大规模临床随机对照研究,已经达成共识,对完全性切除术后的晚期非小细胞肺癌给予以铂为主的术后辅助化疗能够提高患者的生存率,但对于早期的非小细胞肺癌是否给予术后辅助化疗尚存在争议。一些研究认为对于早期的非小细胞肺癌给予术后辅助化疗可以使3年生存率提高3%,使5年生存率提高5%,建议对完全性切除术后的早期非小细胞肺癌给予以铂为主的术后辅助化疗。而另外一些研究发现对完全性切除术后的早期非小细胞肺癌给予术后辅助化疗,不能提高患者的生存率,反而增加了毒性反应和经济负担。
我们认为影响非小细胞肺癌术后辅助化疗效果的原因是患者本身的分子机制不同所致。本研究重心是寻找影响非小细胞肺癌术后辅助化疗效果的分子标志物,建立一个判断非小细胞肺癌术后辅助化疗效果的分子模型以指导早期非小细胞肺癌的术后治疗。并且针对一个有意义的分子指标进行深入研究,探索其作为非小细胞肺癌靶向治疗的潜能。
本研究许多内容在国内尚未有相关报道,为探索性实验,本研究主要由5部分组成。
研究内容
第一部分非小细胞肺癌术后辅助化疗的疗效观察
目的:通过本院近10年的临床资料,分析术后辅助化疗在完全性切除术后的非小细胞肺癌中的意义,并用循证医学方法了解术后辅助化疗在完全性切除术后的早期非小细胞肺癌中的意义。方法:回顾性分析近10年在本院行根治性切除的542例非小细胞肺癌的临床资料,其中268例是Ⅲ期NSCLC,274例是Ⅰ、Ⅱ期NSCLC。通过Medline、CNKI、VIP数据库查找关于早期NSCLC行术后辅助化疗临床随机对照研究,用Review Manager4.2软件进行统计学分析。结果:从本院资料分析显示:对切除术后Ⅲ期NSCLC患者进行3～4周期,以顺铂为基础的化疗方案的辅助化疗,可以提高长期生存率;对根治切除术后Ⅰ、Ⅱ期NSCLC患者不需常规进行辅助化疗。Meta分析显示:共16项研究纳入分析,早期NSCLC完全切除术后加用含铂的辅助化疗方案,不能显著提高患者的生存率。结论:寻找分子标志物以指导早期非小细胞肺癌的术后治疗是一个有意义且亟待解决的研究课题。
第二部分多基因蛋白表达判断早期非小细胞肺癌术后化疗疗效的探讨
目的:目前研究认为与癌症化疗相关的基因有以下六类:(1)药物动力学相关基因;(2)各种生物酶相关基因;(3)DNA损伤与修复相关基因;(4)凋亡相关基因;(5)致癌、抑癌基因;(6)细胞增殖、转移相关基因等,本部分是分析其中的30个基因在早期NSCLC中表达情况,寻找与早期NSCLC术后化疗效果密切相关的基因,通过Logistic回归分析获得一组分子指标以指导早期非小细胞肺癌的术后治疗。方法:利用组织芯片(tissue microarray,TMA)技术和免疫组织化学二步法,对86例行术后辅助化疗的早期非小细胞肺癌标本进行Caspase-3、Fas、Bax、Bcl-2、Survivin、PCNA、Ki67、MGMT、P53、P63、P73、P16、P27、VEGF、nm23、P-gp、MRP、LRP、GST-π、TopoⅡ、C-myc、Cyclin-D1、Her-2、Cox-2、Ku70、Ku80、DNA-PKcs、ERCC1、MSH2、BCRP30种化疗相关蛋白检测。结果:30种化疗相关蛋白在肺癌组织中表达的阳性率为27.9%至91.9%不等。经过单因素分析,与早期NSCLC术后化疗效果密切相关的基因有8个,Survivin、P-gp、LRP、Ki67、P53、ERCC1高表达,NSCLC术后化疗效果差;Bax、VEGF低表达,NSCLC术后化疗效果差。通过Logistic回归分析ERCC1、Survivin、Bax、VEGF4个因子进入方程,方程分类能力达69.8%;方程有效性经卡方检验X~2=29.15,P=0.000。结论:在单因素分析中ERCC1是判断非小细胞肺癌术后辅助化疗效果最敏感的指标,可以进一步深入研究。通过多因素分析ERCC1、Survivin、Bax and VEGF是一组判断非小细胞肺癌术后辅助化疗效果,指导早期非小细胞肺癌的术后治疗的分子指标。对于其可靠性有待于扩大病例进一步研究。
第三部分ERCC1基因在肺癌组织及肺癌细胞系中表达分析
目的:ERCC1是判断非小细胞肺癌术后辅助化疗效果最敏感的指标,本部分首先观察ERCC1基因在肺癌细胞系、肺癌组织与癌旁正常肺组织中表达情况,对ERCC1基因的表达特性有一定了解。然后通过耐药细胞系与亲本细胞系中ERCC1mRNA差别及分析单独行化疗的肺癌中ERCC1基因表达情况,进一步证实ERCC1基因表达与肺癌化疗的关系。方法:首先应用半定量RT-PCR方法检测6株肺癌细胞及30例肺癌组织与癌旁正常肺组织中表达情况。第二使用高浓度反复间歇诱导法建立了对多种化疗药物耐药的细胞系A549/DDP,并用RT-PCR方法检测耐药的细胞系和亲本细胞系中ERCC1表达差别。最后利用免疫组织化学法检测65例单独行化疗的NSCLC中ERCC1表达。结果:与癌旁正常肺组织相比ERCC1在肺癌组织表达明显降低。成功建立了肺癌耐药的细胞系A549/DDP,与亲本细胞A549相比其对常规化疗药物的耐药指数增加了4-5倍,ERCC1在A549/DDP表达明显高于A549细胞。在单独行化疗的NSCLC中,ERCC1表达阳性患者的化疗效果明显差于ERCC1表达阴性患者。结论:ERCC1表达降低可能与肺癌的发生有一定联系,体外细胞实验和体内临床病理分析证实ERCC1基因表达与肺癌化疗密切相关,ERCC1基因表达增高,化疗效果不佳。
第四部分ERCC1基因的初步功能分析
目的:ERCC1是与肺癌化疗密切相关的基因,本部分主要通过基因克隆,细胞转染的技术进一步了解ERCC1基因的生物学功能并初步探讨其引起癌细胞化疗耐受的机制。方法:首先采用基因克隆的方法构建ERCC1基因真核表达载体,用脂质体将载体转染致肺癌细胞H1299中,用G418筛选稳定转染细胞克隆,采用RT-PCR和Western-Blot技术证实ERCC1基因转染成功。第二采用细胞生长曲线,克隆形成实验,细胞侵袭实验,流式细胞仪分析细胞生长周期等方法了解ERCC1基因转染对以上细胞生物学行为的影响。第三采用MTT法检测ERCC1基因转染对各种化疗药物毒性反应的影响。最后利用流式细胞术检测细胞膜蛋白P-gp、MRP的表达,利用高效液相色谱仪检测细胞内药物浓度,探讨ERCC1基因转染引起癌细胞化疗耐受的机制。结果:成功构建ERCC1基因真核表达载体PCDNA3.1/ERCC1,通过筛选建立了稳定转染细胞系H1299/ERCC1和H1299/Vecter。生长曲线、克隆形成实验、细胞侵袭实验、流式细胞仪分析细胞生长周期等实验显示:H1299/ERCC1和H1299/Vecter在以上实验中无差别。化疗药物毒性反应实验显示H1299/ERCC1较H1299/Vecter对顺铂的耐药指数增加4.23倍。流式细胞术检测细胞膜蛋白P-gp、MRP的表达及高效液相色谱仪检测细胞内药物浓度结果显示H1299/ERCC1和H1299/Vecter无明显差异。结论:ERCC1表达与细胞增殖、细胞侵袭、细胞周期失调等特性关系不大。ERCC1基因表达增高,细胞可以出现化疗耐药,初步研究显示ERCC1基因导致的化疗耐药并非传统的耐药机制(如膜转运蛋白表达差异)使药物摄入减少及外排增加引起,可能与DNA损伤与修复机制改变有关。
第五部分RNA干扰抑制肺癌细胞ERCC1基因表达的初步功能分析
目的:ERCC1基因在肺癌细胞的各种生物学行为中并不扮演重要角色,其改变主要是引起细胞对化疗药物的敏感性改变,是功能比较单一的基因,可能是提高非小细胞肺癌化疗疗效的一个有潜质的新靶点。本部分主要通过RNA干扰技术抑制肺癌细胞ERCC1基因表达,进行初步功能实验。方法:首先通过构建ERCC1基因及β-actin基因的克隆载体作为标准品,建立ERCC1基因荧光实时定量PCR检测平台。第二构建针对ERCC1基因的SiRNA真核表达载体,瞬时转染肺癌细胞A549,采用RT-PCR和Western-Blot技术证实转染细胞中ERCC1基因沉默效果良好。最后采用MTT法检测构建真核表达载体转染细胞对顺铂药物毒性反应的影响。结果:荧光实时定量PCR能够准确检测样本中ERCC1基因的mRNA表达水平。成功构建针对ERCC1基因的SiRNA真核表达载体,将其转染肺癌细胞A549,可以抑制细胞中ERCC1基因表达。RNA干扰的A549细胞较亲本细胞对顺铂的耐药指数降低了2.93倍。结论:RNA干扰是一种沉默ERCC1表达的理想方法。沉默ERCC1表达可以提高肺癌细胞的化疗敏感性,它可能是一种有潜质的肺癌辅助治疗新方法。
[Background]
The malignant tumor is one of the severe diseases which are harmful to the health of human beings.The investigation of the death causes shows that the death rate of lung cancer is more rapidly increasing in last twenty years,Now lung cancer is usually treated with local measures including surgery,chemotherapy,radiotherapy and immunotherapy.Chemotherapy as a systemic therapy means can not be replaced by surgery and radiotherapy as for the therapies of malignant tumors.Several randomized trials now have confirmed the survival benefit with adjuvant platinum-based chemotherapy for patients with late-stage NSCLC.The role of adjuvant chemotherapy in patients with completely resected Early-Stage NSCLC is unclear.
A recent meta-analysis of all randomised trials showed that the absolute risk of death was reduced by 3%at 3 years and 5%at 5 years for patients who were treated with postoperative cisplatin-containing regimens compared to patients who were treated with surgery alone.On these bases,some institutions,in spite of drug toxicity,proposed the introduction of adjuvant chemotherapy even after presumed radical surgery at stage I NSCLC.Nevertheless,according to another multicentric study,there was no significant effect on survival;hence the toxicity induced by chemotherapy appeared to radically operated patients,especially for those at stage I NSCLC,to be too high cost to pay.
our researches focused on the molecular mechnism of adjuvant chemotherapy in patients with completely resected Early-Stage NSCLC.we try to develop methods to judge the effect of adjuvant chemotherapy and guide the treatment to this patient.
No documents has been published on such a study till now.This provided vacuum for our expriment.So the present study proceed five parts.
[Study]
PartⅠClinical Analysis of adjuvant chemotherapy in patients with completely resected NSCLC in 10 Years and meta-analysis of Adjuvant Chemotherapy with Complete Resection for Early-Stage NSCLC
Objective.To evaluate the effect of adjuvant chemotherapy after radical surgery for NSCLC and analyze the factor that effect the adjuvant chemotherapy.Methods:we analysed clinical data in 542 cases of NSCLC undergone resectional surgery in our hospitol.268 patients isⅢNSCLC and 274 patients isⅠ、ⅡNSCLC.Domestic and overseas literatures were reviewed to collecte correlative study data of adjuvant chemotherapy or solitary opration for Early-Stage NSCLC.
3-year survival times of the two treatment methods were meta analyzed with Review manager 4.2 according to the data of literatures.Results:1\To stageⅢNSCLC patients administer adjuvant chemotherapy with platinum-based regimen for 3 or 4 cycles can improve survival rate.2\ To stageⅠ,ⅡNSCLC patients administer adjuvant chemotherapy is not a recommended therapy methods.3\ The effectiveness of some adjuvant chemotherapy regimens with complete resection in patients with NSCLC has been improved.Conclusion:it is a important work to looking for molecular marker guide the treatment the patient with completely resected Early-Stage NSCLC.
PartⅡStudy on the Relationship between Combined Multigene Detection and Response to Chemotherapy and Prognosis in Early-Stage non-small cell lung cancer tissues
objective:Many studies have show that 30 genes expression associated to chemotherapy in cancer.in this study we detect the 30 genes expression in the patient with completely resected Early-Stage NSCLC follow by adjuvant chemotherapy.in order to fine the molecular marker relation to adjuvant chemotherapy Methods:The tissue microarray technique was used to prepare for tissue microarray in 86 cases of Early-Stage NSCLC that received adjuvant chemotherapy after undergone radical surgery.The expressions of Caspase-3、Fas、Bax、Bcl-2、Survivin、PCNA、Ki67、MGMT、P53、P63、P73、P16、P27、VEGF、nm23、P-gp、MRP、LRP、GST-π、TopoⅡ、C-myc、Cyclin-D1、Her-2、Cox-2、Ku70、Ku80、DNA-PKcs、ERCC1、MSH2、BCRP proteins were detected using immunohistochemical two-step method.Results:The positive rate of 30 genes in lung cancer tissue were 27.9%-91.9%respectively.There are 8 genes expression was related to NSCLC adjuvant chemotherapy.The higher expressing intensity of Survivin、P-gp、LRP、Ki67、P53 and ERCC1,the lower 3-year survival rate in NSCLC,there was significant discrepancy(P＞0.05). The higher expressing intensity of Bax and VEGF,the higher 3-year survival rate in NSCLC,there was significant discrepancy(P＞0.05).by logistic regression analysis the ERCC1、Survivin、Bax and VEGF are good group for predict the effective of adjuvant chemotherapy in Early-Stage NSCLC.Conclusion.ERCC1 is the most sensitivity marker to judge effect of adjuvant chemotherapy and it is ideal marker to be deeply research. Survivin、ERCC1、Bax and VEGF are ideal group factor that effect the adjuvant chemotherapy and their must be comfirn by deeply research.
PartⅢA study on the expression of ERCC1 gene in human non-small cell lung cancer tissues and cell lines
objective:The aim of this study is to study the mRNA expression of ERCC1 in human lung cancer tissues and normal lung tissues.and to investigate the relationship between ERCC1 protein expression and the effect of chemotherapy to NSCLC in vivo or vitro.Methods:1\ Semi-quantification expression analysis of ERCC1 mRNA in human lung cancer and corresponding normal lung tissues were performed by RT-PCR and electrophoresis band opacity density comparison analysis.2\ Establishment of an DDP-resistant human NSCLC cell line A549/DDP by high does interval inactivated methods.3\ Semi-quantification expression analysis of ERCC1 mRNA in A549/DDP and corresponding A549 were performed by RT-PCR.4\ The expressions of ERCC1 protein in 64 cases of NSCLC that received chemotherapy alone were detected using immunohistochemical two-step method.Results: 1\ The mRNA expression of ERCC1 gene decreased significantly in human lung cancer tissue compared withthat in normal lung tissue.2\ DDP-resistant human NSCLC cell line A549/DDP were established and the values of IC50 of resistant cells to relative drugs were elevated 4-5 times.3\ The mRNA expression of ERCC1 gene increased significantly in A549/DDP compared with A549.4\ The protein expression of ERCC1 gene in good effect group of NSCLC is significantly lower than bed effect group patients.Conclusion:the ERCC1 is lower expression gene in lung cancer compared to lung tissue,the ERCC1 protein expression is relationship to the effect of chemotherapy to NSCLC in vivo or vitro.
PartⅣStudy on biological effects of ERCC1 in lung cancer cells
objective:Study on biological effects of ERCC1 in lung cancer cells by gene clone technich.Methods:1\ the ERCC1 expression vector were established and introduced into H1299 cells by liposome transfection reagent.Positive clones were screened with G418.RT-PCR was used to confirm whether the recombinant vector DNA integrated with the genomic DNA of H1299 cells.Western-blot was used to confirm whether the clone gene expression in Positive clones cells.2\ The cell growth curves,clonogenicity efficiency in plating and the cell cycle were measured to observe the changes in cell proliferation.3\The characteristic of drug resistance in stable transfection cell were measured by MTT assay.4\ Intracellular concentrations of chemotherapy drugs were detected using high-performance liquid chromatography.5\The expression of resistant gene P-pg and MRP in stable transfection cell were measured by Flow Cytometry method.Results:1\ the ERCC1 expression vector were identified by the sequence analysis.2\the Positive clones H1299/ERCC1 and H1299/vecter were confirm by RT-PCR and Western-blot.3\ The characteristic of cell proliferation was not change in H1299/ERCC1 and H1299/vecter.4\ the values of IC50 of H1299/ERCC1 to chemotherapy drugs were elevated 4.23 times than H1299/vecter.5\ Intracellular concentrations of chemotherapy drugs and The expression of resistant gene P-pg and MRP were not different between H1299/ERCC1 and H1299/vecter..Conclusion:the ERCC1 function is not relactive to cell proliferation.The expression of ERCC1 can improve capitent of resistant chemotherapy drugs in lung cancer cell.The mechnism of resistant chemotherapy drugs in ERCC1 expression cell not relative to change of Intracellular concentrations of chemotherapy drugs and change of expression of resistant gene P-pg and MRP.
PartⅤ:Effects of RNA interference on ERCC1 expression in non-small-cell lung cancer cells in vitro
objective.To investigate whether RNA interference(RNAi)could induce gene silencing in non-small-cell lung cancer(NSCLC)cells as well as assess the degree of ERCC1 gene silencing and its effect on functional outcome..Methods:1\ The methods of detect expression of ERCC1 gene by Fluorescence real-time quantitative PCR(FQ-PCR)are constructed satisfactorily.2\the small interference RNA(siRNA)of ERCC1 expression vector were established and introduced into lung cancer cells(A549)by liposome transfection reagent. RT-PCR and Western-blot were used to confirm whether the siRNA silencing the expression of ERCC1 in A549 cell.3\ The characteristic of drug resistance in instantaneous transfection cell were measured by MTT assay.Results:1\ the FQ-PCR can be applied to detect expression of ERCC1 gene accurately.2\ the siRNA of ERCC1 expression vector were identified by the sequence analysis.3\ RT-PCR and Western-blot assay show that the expression of ERCC1 in instantaneous transfection cell were significantly lower than not siRNA of ERCC1 transfection cell.4\ the values of IC50 of A549/siRNA to chemotherapy drugs were decrease 2.93 times than A549/vecter.Conclusion.the RNA interference to ERCC1 gene is a good method to silence expression of ERCC1 in lung cancer cell.inhibit the expression of ERCC1 can enhance sensitivity to chemotherapy drugs in lung cancer cell.it may be a available therapeutic modalities in the treatment of lung cancer.
恶性肿瘤是目前危害人类健康最严重疾病之一。近二十年全国性死亡原因调查显示,死亡率上升幅度最大的是肺癌。目前肺癌的治疗一般采用手术、化疗、放疗、免疫治疗等综合措施,其中化疗作为全身性治疗手段,在恶性肿瘤的治疗中具有手术和放疗不能替代的地位。经过长期的临床经验总结和一些大规模临床随机对照研究,已经达成共识,对完全性切除术后的晚期非小细胞肺癌给予以铂为主的术后辅助化疗能够提高患者的生存率,但对于早期的非小细胞肺癌是否给予术后辅助化疗尚存在争议。一些研究认为对于早期的非小细胞肺癌给予术后辅助化疗可以使3年生存率提高3%,使5年生存率提高5%,建议对完全性切除术后的早期非小细胞肺癌给予以铂为主的术后辅助化疗。而另外一些研究发现对完全性切除术后的早期非小细胞肺癌给予术后辅助化疗,不能提高患者的生存率,反而增加了毒性反应和经济负担。
我们认为影响非小细胞肺癌术后辅助化疗效果的原因是患者本身的分子机制不同所致。本研究重心是寻找影响非小细胞肺癌术后辅助化疗效果的分子标志物,建立一个判断非小细胞肺癌术后辅助化疗效果的分子模型以指导早期非小细胞肺癌的术后治疗。并且针对一个有意义的分子指标进行深入研究,探索其作为非小细胞肺癌靶向治疗的潜能。
本研究许多内容在国内尚未有相关报道,为探索性实验,本研究主要由5部分组成。
研究内容
第一部分非小细胞肺癌术后辅助化疗的疗效观察
目的:通过本院近10年的临床资料,分析术后辅助化疗在完全性切除术后的非小细胞肺癌中的意义,并用循证医学方法了解术后辅助化疗在完全性切除术后的早期非小细胞肺癌中的意义。方法:回顾性分析近10年在本院行根治性切除的542例非小细胞肺癌的临床资料,其中268例是Ⅲ期NSCLC,274例是Ⅰ、Ⅱ期NSCLC。通过Medline、CNKI、VIP数据库查找关于早期NSCLC行术后辅助化疗临床随机对照研究,用Review Manager4.2软件进行统计学分析。结果:从本院资料分析显示:对切除术后Ⅲ期NSCLC患者进行3～4周期,以顺铂为基础的化疗方案的辅助化疗,可以提高长期生存率;对根治切除术后Ⅰ、Ⅱ期NSCLC患者不需常规进行辅助化疗。Meta分析显示:共16项研究纳入分析,早期NSCLC完全切除术后加用含铂的辅助化疗方案,不能显著提高患者的生存率。结论:寻找分子标志物以指导早期非小细胞肺癌的术后治疗是一个有意义且亟待解决的研究课题。
第二部分多基因蛋白表达判断早期非小细胞肺癌术后化疗疗效的探讨
目的:目前研究认为与癌症化疗相关的基因有以下六类:(1)药物动力学相关基因;(2)各种生物酶相关基因;(3)DNA损伤与修复相关基因;(4)凋亡相关基因;(5)致癌、抑癌基因;(6)细胞增殖、转移相关基因等,本部分是分析其中的30个基因在早期NSCLC中表达情况,寻找与早期NSCLC术后化疗效果密切相关的基因,通过Logistic回归分析获得一组分子指标以指导早期非小细胞肺癌的术后治疗。方法:利用组织芯片(tissue microarray,TMA)技术和免疫组织化学二步法,对86例行术后辅助化疗的早期非小细胞肺癌标本进行Caspase-3、Fas、Bax、Bcl-2、Survivin、PCNA、Ki67、MGMT、P53、P63、P73、P16、P27、VEGF、nm23、P-gp、MRP、LRP、GST-π、TopoⅡ、C-myc、Cyclin-D1、Her-2、Cox-2、Ku70、Ku80、DNA-PKcs、ERCC1、MSH2、BCRP30种化疗相关蛋白检测。结果:30种化疗相关蛋白在肺癌组织中表达的阳性率为27.9%至91.9%不等。经过单因素分析,与早期NSCLC术后化疗效果密切相关的基因有8个,Survivin、P-gp、LRP、Ki67、P53、ERCC1高表达,NSCLC术后化疗效果差;Bax、VEGF低表达,NSCLC术后化疗效果差。通过Logistic回归分析ERCC1、Survivin、Bax、VEGF4个因子进入方程,方程分类能力达69.8%;方程有效性经卡方检验X~2=29.15,P=0.000。结论:在单因素分析中ERCC1是判断非小细胞肺癌术后辅助化疗效果最敏感的指标,可以进一步深入研究。通过多因素分析ERCC1、Survivin、Bax and VEGF是一组判断非小细胞肺癌术后辅助化疗效果,指导早期非小细胞肺癌的术后治疗的分子指标。对于其可靠性有待于扩大病例进一步研究。
第三部分ERCC1基因在肺癌组织及肺癌细胞系中表达分析
目的:ERCC1是判断非小细胞肺癌术后辅助化疗效果最敏感的指标,本部分首先观察ERCC1基因在肺癌细胞系、肺癌组织与癌旁正常肺组织中表达情况,对ERCC1基因的表达特性有一定了解。然后通过耐药细胞系与亲本细胞系中ERCC1mRNA差别及分析单独行化疗的肺癌中ERCC1基因表达情况,进一步证实ERCC1基因表达与肺癌化疗的关系。方法:首先应用半定量RT-PCR方法检测6株肺癌细胞及30例肺癌组织与癌旁正常肺组织中表达情况。第二使用高浓度反复间歇诱导法建立了对多种化疗药物耐药的细胞系A549/DDP,并用RT-PCR方法检测耐药的细胞系和亲本细胞系中ERCC1表达差别。最后利用免疫组织化学法检测65例单独行化疗的NSCLC中ERCC1表达。结果:与癌旁正常肺组织相比ERCC1在肺癌组织表达明显降低。成功建立了肺癌耐药的细胞系A549/DDP,与亲本细胞A549相比其对常规化疗药物的耐药指数增加了4-5倍,ERCC1在A549/DDP表达明显高于A549细胞。在单独行化疗的NSCLC中,ERCC1表达阳性患者的化疗效果明显差于ERCC1表达阴性患者。结论:ERCC1表达降低可能与肺癌的发生有一定联系,体外细胞实验和体内临床病理分析证实ERCC1基因表达与肺癌化疗密切相关,ERCC1基因表达增高,化疗效果不佳。
第四部分ERCC1基因的初步功能分析
目的:ERCC1是与肺癌化疗密切相关的基因,本部分主要通过基因克隆,细胞转染的技术进一步了解ERCC1基因的生物学功能并初步探讨其引起癌细胞化疗耐受的机制。方法:首先采用基因克隆的方法构建ERCC1基因真核表达载体,用脂质体将载体转染致肺癌细胞H1299中,用G418筛选稳定转染细胞克隆,采用RT-PCR和Western-Blot技术证实ERCC1基因转染成功。第二采用细胞生长曲线,克隆形成实验,细胞侵袭实验,流式细胞仪分析细胞生长周期等方法了解ERCC1基因转染对以上细胞生物学行为的影响。第三采用MTT法检测ERCC1基因转染对各种化疗药物毒性反应的影响。最后利用流式细胞术检测细胞膜蛋白P-gp、MRP的表达,利用高效液相色谱仪检测细胞内药物浓度,探讨ERCC1基因转染引起癌细胞化疗耐受的机制。结果:成功构建ERCC1基因真核表达载体PCDNA3.1/ERCC1,通过筛选建立了稳定转染细胞系H1299/ERCC1和H1299/Vecter。生长曲线、克隆形成实验、细胞侵袭实验、流式细胞仪分析细胞生长周期等实验显示:H1299/ERCC1和H1299/Vecter在以上实验中无差别。化疗药物毒性反应实验显示H1299/ERCC1较H1299/Vecter对顺铂的耐药指数增加4.23倍。流式细胞术检测细胞膜蛋白P-gp、MRP的表达及高效液相色谱仪检测细胞内药物浓度结果显示H1299/ERCC1和H1299/Vecter无明显差异。结论:ERCC1表达与细胞增殖、细胞侵袭、细胞周期失调等特性关系不大。ERCC1基因表达增高,细胞可以出现化疗耐药,初步研究显示ERCC1基因导致的化疗耐药并非传统的耐药机制(如膜转运蛋白表达差异)使药物摄入减少及外排增加引起,可能与DNA损伤与修复机制改变有关。
第五部分RNA干扰抑制肺癌细胞ERCC1基因表达的初步功能分析
目的:ERCC1基因在肺癌细胞的各种生物学行为中并不扮演重要角色,其改变主要是引起细胞对化疗药物的敏感性改变,是功能比较单一的基因,可能是提高非小细胞肺癌化疗疗效的一个有潜质的新靶点。本部分主要通过RNA干扰技术抑制肺癌细胞ERCC1基因表达,进行初步功能实验。方法:首先通过构建ERCC1基因及β-actin基因的克隆载体作为标准品,建立ERCC1基因荧光实时定量PCR检测平台。第二构建针对ERCC1基因的SiRNA真核表达载体,瞬时转染肺癌细胞A549,采用RT-PCR和Western-Blot技术证实转染细胞中ERCC1基因沉默效果良好。最后采用MTT法检测构建真核表达载体转染细胞对顺铂药物毒性反应的影响。结果:荧光实时定量PCR能够准确检测样本中ERCC1基因的mRNA表达水平。成功构建针对ERCC1基因的SiRNA真核表达载体,将其转染肺癌细胞A549,可以抑制细胞中ERCC1基因表达。RNA干扰的A549细胞较亲本细胞对顺铂的耐药指数降低了2.93倍。结论:RNA干扰是一种沉默ERCC1表达的理想方法。沉默ERCC1表达可以提高肺癌细胞的化疗敏感性,它可能是一种有潜质的肺癌辅助治疗新方法。
[Background]
The malignant tumor is one of the severe diseases which are harmful to the health of human beings.The investigation of the death causes shows that the death rate of lung cancer is more rapidly increasing in last twenty years,Now lung cancer is usually treated with local measures including surgery,chemotherapy,radiotherapy and immunotherapy.Chemotherapy as a systemic therapy means can not be replaced by surgery and radiotherapy as for the therapies of malignant tumors.Several randomized trials now have confirmed the survival benefit with adjuvant platinum-based chemotherapy for patients with late-stage NSCLC.The role of adjuvant chemotherapy in patients with completely resected Early-Stage NSCLC is unclear.
A recent meta-analysis of all randomised trials showed that the absolute risk of death was reduced by 3%at 3 years and 5%at 5 years for patients who were treated with postoperative cisplatin-containing regimens compared to patients who were treated with surgery alone.On these bases,some institutions,in spite of drug toxicity,proposed the introduction of adjuvant chemotherapy even after presumed radical surgery at stage I NSCLC.Nevertheless,according to another multicentric study,there was no significant effect on survival;hence the toxicity induced by chemotherapy appeared to radically operated patients,especially for those at stage I NSCLC,to be too high cost to pay.
our researches focused on the molecular mechnism of adjuvant chemotherapy in patients with completely resected Early-Stage NSCLC.we try to develop methods to judge the effect of adjuvant chemotherapy and guide the treatment to this patient.
No documents has been published on such a study till now.This provided vacuum for our expriment.So the present study proceed five parts.
[Study]
PartⅠClinical Analysis of adjuvant chemotherapy in patients with completely resected NSCLC in 10 Years and meta-analysis of Adjuvant Chemotherapy with Complete Resection for Early-Stage NSCLC
Objective.To evaluate the effect of adjuvant chemotherapy after radical surgery for NSCLC and analyze the factor that effect the adjuvant chemotherapy.Methods:we analysed clinical data in 542 cases of NSCLC undergone resectional surgery in our hospitol.268 patients isⅢNSCLC and 274 patients isⅠ、ⅡNSCLC.Domestic and overseas literatures were reviewed to collecte correlative study data of adjuvant chemotherapy or solitary opration for Early-Stage NSCLC.
3-year survival times of the two treatment methods were meta analyzed with Review manager 4.2 according to the data of literatures.Results:1\To stageⅢNSCLC patients administer adjuvant chemotherapy with platinum-based regimen for 3 or 4 cycles can improve survival rate.2\ To stageⅠ,ⅡNSCLC patients administer adjuvant chemotherapy is not a recommended therapy methods.3\ The effectiveness of some adjuvant chemotherapy regimens with complete resection in patients with NSCLC has been improved.Conclusion:it is a important work to looking for molecular marker guide the treatment the patient with completely resected Early-Stage NSCLC.
PartⅡStudy on the Relationship between Combined Multigene Detection and Response to Chemotherapy and Prognosis in Early-Stage non-small cell lung cancer tissues
objective:Many studies have show that 30 genes expression associated to chemotherapy in cancer.in this study we detect the 30 genes expression in the patient with completely resected Early-Stage NSCLC follow by adjuvant chemotherapy.in order to fine the molecular marker relation to adjuvant chemotherapy Methods:The tissue microarray technique was used to prepare for tissue microarray in 86 cases of Early-Stage NSCLC that received adjuvant chemotherapy after undergone radical surgery.The expressions of Caspase-3、Fas、Bax、Bcl-2、Survivin、PCNA、Ki67、MGMT、P53、P63、P73、P16、P27、VEGF、nm23、P-gp、MRP、LRP、GST-π、TopoⅡ、C-myc、Cyclin-D1、Her-2、Cox-2、Ku70、Ku80、DNA-PKcs、ERCC1、MSH2、BCRP proteins were detected using immunohistochemical two-step method.Results:The positive rate of 30 genes in lung cancer tissue were 27.9%-91.9%respectively.There are 8 genes expression was related to NSCLC adjuvant chemotherapy.The higher expressing intensity of Survivin、P-gp、LRP、Ki67、P53 and ERCC1,the lower 3-year survival rate in NSCLC,there was significant discrepancy(P＞0.05). The higher expressing intensity of Bax and VEGF,the higher 3-year survival rate in NSCLC,there was significant discrepancy(P＞0.05).by logistic regression analysis the ERCC1、Survivin、Bax and VEGF are good group for predict the effective of adjuvant chemotherapy in Early-Stage NSCLC.Conclusion.ERCC1 is the most sensitivity marker to judge effect of adjuvant chemotherapy and it is ideal marker to be deeply research. Survivin、ERCC1、Bax and VEGF are ideal group factor that effect the adjuvant chemotherapy and their must be comfirn by deeply research.
PartⅢA study on the expression of ERCC1 gene in human non-small cell lung cancer tissues and cell lines
objective:The aim of this study is to study the mRNA expression of ERCC1 in human lung cancer tissues and normal lung tissues.and to investigate the relationship between ERCC1 protein expression and the effect of chemotherapy to NSCLC in vivo or vitro.Methods:1\ Semi-quantification expression analysis of ERCC1 mRNA in human lung cancer and corresponding normal lung tissues were performed by RT-PCR and electrophoresis band opacity density comparison analysis.2\ Establishment of an DDP-resistant human NSCLC cell line A549/DDP by high does interval inactivated methods.3\ Semi-quantification expression analysis of ERCC1 mRNA in A549/DDP and corresponding A549 were performed by RT-PCR.4\ The expressions of ERCC1 protein in 64 cases of NSCLC that received chemotherapy alone were detected using immunohistochemical two-step method.Results: 1\ The mRNA expression of ERCC1 gene decreased significantly in human lung cancer tissue compared withthat in normal lung tissue.2\ DDP-resistant human NSCLC cell line A549/DDP were established and the values of IC50 of resistant cells to relative drugs were elevated 4-5 times.3\ The mRNA expression of ERCC1 gene increased significantly in A549/DDP compared with A549.4\ The protein expression of ERCC1 gene in good effect group of NSCLC is significantly lower than bed effect group patients.Conclusion:the ERCC1 is lower expression gene in lung cancer compared to lung tissue,the ERCC1 protein expression is relationship to the effect of chemotherapy to NSCLC in vivo or vitro.
PartⅣStudy on biological effects of ERCC1 in lung cancer cells
objective:Study on biological effects of ERCC1 in lung cancer cells by gene clone technich.Methods:1\ the ERCC1 expression vector were established and introduced into H1299 cells by liposome transfection reagent.Positive clones were screened with G418.RT-PCR was used to confirm whether the recombinant vector DNA integrated with the genomic DNA of H1299 cells.Western-blot was used to confirm whether the clone gene expression in Positive clones cells.2\ The cell growth curves,clonogenicity efficiency in plating and the cell cycle were measured to observe the changes in cell proliferation.3\The characteristic of drug resistance in stable transfection cell were measured by MTT assay.4\ Intracellular concentrations of chemotherapy drugs were detected using high-performance liquid chromatography.5\The expression of resistant gene P-pg and MRP in stable transfection cell were measured by Flow Cytometry method.Results:1\ the ERCC1 expression vector were identified by the sequence analysis.2\the Positive clones H1299/ERCC1 and H1299/vecter were confirm by RT-PCR and Western-blot.3\ The characteristic of cell proliferation was not change in H1299/ERCC1 and H1299/vecter.4\ the values of IC50 of H1299/ERCC1 to chemotherapy drugs were elevated 4.23 times than H1299/vecter.5\ Intracellular concentrations of chemotherapy drugs and The expression of resistant gene P-pg and MRP were not different between H1299/ERCC1 and H1299/vecter..Conclusion:the ERCC1 function is not relactive to cell proliferation.The expression of ERCC1 can improve capitent of resistant chemotherapy drugs in lung cancer cell.The mechnism of resistant chemotherapy drugs in ERCC1 expression cell not relative to change of Intracellular concentrations of chemotherapy drugs and change of expression of resistant gene P-pg and MRP.
PartⅤ:Effects of RNA interference on ERCC1 expression in non-small-cell lung cancer cells in vitro
objective.To investigate whether RNA interference(RNAi)could induce gene silencing in non-small-cell lung cancer(NSCLC)cells as well as assess the degree of ERCC1 gene silencing and its effect on functional outcome..Methods:1\ The methods of detect expression of ERCC1 gene by Fluorescence real-time quantitative PCR(FQ-PCR)are constructed satisfactorily.2\the small interference RNA(siRNA)of ERCC1 expression vector were established and introduced into lung cancer cells(A549)by liposome transfection reagent. RT-PCR and Western-blot were used to confirm whether the siRNA silencing the expression of ERCC1 in A549 cell.3\ The characteristic of drug resistance in instantaneous transfection cell were measured by MTT assay.Results:1\ the FQ-PCR can be applied to detect expression of ERCC1 gene accurately.2\ the siRNA of ERCC1 expression vector were identified by the sequence analysis.3\ RT-PCR and Western-blot assay show that the expression of ERCC1 in instantaneous transfection cell were significantly lower than not siRNA of ERCC1 transfection cell.4\ the values of IC50 of A549/siRNA to chemotherapy drugs were decrease 2.93 times than A549/vecter.Conclusion.the RNA interference to ERCC1 gene is a good method to silence expression of ERCC1 in lung cancer cell.inhibit the expression of ERCC1 can enhance sensitivity to chemotherapy drugs in lung cancer cell.it may be a available therapeutic modalities in the treatment of lung cancer.
引文
1 孙燕,主编.内科肿瘤学口.北京:人民卫生出版社,2001.640-673.
2 Parkin DM.Global cancer statistics in the year of 2000[J].Lancet Oncol,2001,2(9):543-552.
3 周际昌,主编.实用肿瘤内科学.北京:人民卫生出版社,2003.543-552.
4 廖美琳.周允中.严德钧等Ⅰ期NSCLC术后辅助治疗的研究.中国癌症杂志,1998.8:66-69.
5 Munehisa Imaizumi.Postoperative adjuvant cisplatin,vindesine,plus uracil tegafur chemotherapy increased survival of patients with completely resected p-stage Ⅰ non-small cell lung cancer.Lung Cancer(2005)49,85-94.
6 Socinski MA,Kies M,Schell MJ.et al Duration of therapy in stage ⅢB non small cell Lung cancer(NSCLC)a multi-institutional phase Ⅱtrial,Proc Am SOC clin Oncol.2001,20:309A.
7 Smith JE,Brien MER,Talboe DC.et al.Duration of Chemotherapy in Aduvanced Non-Small-Cell-Lung Cancer:A Randomized Trial of Three Verse Six Course of Mitimycin,Vinblastine.and Cisplatin.J Clin()ncol,2001,19(3):1336-1343.
8 Wada H,Tanaka F,Hitomi S,et al.Postoperative adjuvant chemotherapy for non-small-cell lung cancer.West Japan Study Group for Lung Cancer Surgery.The Japan Lung Cancer Research Group on Post surgical Adjuvant Chemotherapy[J].Oncology (Huntingt).1997,11(9 Suppl 10):98-102.
9 Endo C,Saito Y,wanami H,et al.A randomized trial of postoperative UFT therapy in P stage Ⅰ.Ⅱ non-small-cell lung cancer:North-east Japan Study Group for Lung Cancer Surgery[J].Lung Cancer,2003,40(2):181-186.
10 Kato H,Tsuboi M,Ohta M,et al.A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage Ⅰ(T1NOM0,T2N0M0)adenocarcinoma of the lung[J].Proc Am Soc Clin Oncol.2003,23:2498a.
11 吴一龙,廖美琳,周清华 非小细胞肺癌术后辅助治疗共识 循证医学2004,4(4):256-238.
12 吴一龙.肿癌多学科综合治疗的理论与实践[M].北京:人民卫生出版社,2000.195-198.
13 Keller,SM,Adak,S,Wagner,H,et al A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or Ⅲa non-small-cell lung cancer.N Engl J Med 2000;343,1217-1222.
14 Wolf M,Mailer H H,Seifart U,et al.Randomized phase Ⅲ trial of adjuvant radiotherapy vs adjuvant chemotherapy followed by radiotherapy in patients with N2 positive non small cell lung cancer(NSCLC).Proc Am Soc Clin Oncol.2001,20:1242a
15 Ichinose Y,Taga H,Koike T,etal.Chemotherapy in patients with completely resected stage Ⅲa N2 non small cell lung cancer:japan clinical oncology group(JCOG)trial[A].Proc Am Soc Clin Oncol.2001,20:1241a.
16 Scagliotti GV,Fossati R,Torri V,etal.Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ,Ⅱ,or Ⅲa Non-Small Cell Lung Cancer.J Natl Cancer Inst,2003,95(19):1453-1461.
17 The International Adjuvant Lung Cancer Trial Collaborative Group.Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer.N Engl J Med.2004;350(4):351-60.
18 Winton T,Livingston R,Johnson D,etal.A prospective randomized trial of ajuvant vinorelbine(VIN)and cisplatin(CIS)in completely resected stage ⅠB and Ⅱ non-small cell lung cancer(NSCLC)Intergroup JBR 10[C].Proc Am Soc Clin Oncol,2004,23(suppl):17.7018a.
19 Strauss,GM,Herndon,J,Maddaus,MA,et al.Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage ⅠB non-small cell lung cancer(NSCLC):report of Cancer and Leukemia Group B(CALGB)Protocol 9633.J Clin Oncol 2004;22,621-c.
20 non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J].BMJ,1995,311:899-909.
21 廖日强,吴一龙,杨学宁,等。非小细胞肺癌完全切除术后含铂化疗方案的累积meta分析.循证医学,2003,3(4):196-203.
22 Douglas West,Alan JB,Joel Dunning.Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival.Interact Cardio Vasc Thorac Surg 2006;5:488-492.
23 Desmond N.Carney Lung Cancer-Time to Move on from Chemotherapy The new England journal of medicain 2002,346:126-128.
24 Luqmani YA.Mechanisms of drug resistance in cancer chemotherapy.Med Princ Pract.2005;Suppl 1:35-48.
25 Chintamani,Singh JP,Mittal MK,et al.Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study.World J Surg Oncol.2005,3:61-67.
26 Gan HZ,Zhang GZ,Zhao JS,et al.Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.Chin Med J(Engl).2005;118(11):893-902.
27 Kong JX,Song Q,Liu YP,et al.Inhibition of multidrug resistance gene 1 expression in glioma by antisense oligodeoxynucleotides。Zhongguo Yi Xue Ke Xue Yuan Xue Bao.2005 27(2):211-215.
28 Xiang Y,Li L,Tian F,Yang XY,et al.Improving P-gp expression in human mononuclear cells in vitro transfected by multidrug resistance-1 mRNA.Chin Med Sci J.2005;20(1):48-50.
29 孔肇路,金一尊.多药耐药相关蛋白的生物学特性与作用机制的研究进展.中国癌症杂志 2001;11:375-378.
30 Leah C.Young,Barbara G.Campling,Susan P.C.Cole,et al Multidrug Resistance Proteins MRP3,MRP1,and MRP2 in Lung Cancer Correlation of Protein Levels with Drug Response and Messenger RNA Levels Clinical Cancer Research 2001,7:1798-1804.
31 Z.P.Lin,D.R.Johnson,R.A.Finch,et al Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts Molecular Cancer Therapeutic,2002,1(12):1105-1114.
32 Izquierdo GL,Wingaard PLJ,Flens MJ,et al.Relationship of LRP human major vault protein to in vitro and clinical resistance to anticancer drug.Cytotechnology,1996,19(3):191-197
33 吕梅君,王洁,易祥华,等.肺癌耐药蛋白在非小细胞肺癌中的表达与临床相关性 研究[J].中华结核和呼吸杂志,2001,24(8):458-459.
34 Boutonnat J,Bonnefoix T,Mousseau,et al.Coexpression of multidrug resistance involve protein:a flow cytometric analysis[J].AnticancerRes,1998,18(4):2993-2999.
35 Ross DD,Yasng W,Abruzzo LV,et al.A typical multidrug resistance:breastcancer resistance protein messenger RNA expression in mitoxantrone-selected ovarian tumor cell line.J Natl Cancer Inst,1999,91:429.
36 Schellens JH,Maliepaard M,Scheper RJ,et al.Transport of topoisomerase I inhibitors by the breast cancer resistance protein.Potential clinical implications.Ann N Y Acad Sci 2000;922:188-94.
37 尚世丽,刘云鹏,于秉治.蛋白激酶C与P-糖蛋白介导的肿瘤多药耐药.国外医学药学分册.2000;27:5-7.
38 Sonnemann J.Gekeler V,Ahlbrecht K,et al.Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitizes A549 lung cancer cells to vincristine and paclitaxel.Cancer Lett,2004,29(2):177-185.
39 Ding L,Wang H,Lang W,et al.Protein 15 kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway.J Biol Chem,2002,277 16(38):35305-35313.
40 Kigawa J,Takahashi M,Minagawa Y,et al.Topoisomerase-Ⅰ activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.Int J Cancer 1999 Oct 22;84(5):521-524.
41 Yanase K,Sugimoto Y,Andoh T,et al.Retroviral expression of a mutant(Gly-533)human DNA topoisomerase Ⅰ cDNA confers a dominant form of camptothecin resistance.Int J Cancer 1999 Mar 31;81(1):134-40.
42 Boutonnat J,Bonnefoix T,Mousseau,et al.Coexpression of multidrug resistance involve protein:a flow cytometric analysis[J].Anticancer Res,1998,18(4):2993-2999.
43 李颢,徐健.谷胱甘肽-S-转移酶与白血病耐药.国外医学肿瘤学分册.1999;26:184-185.
44 周清,薛亚梅,张治.谷胱甘肽S转移酶与肺癌关系若干研究进展.国外医学临床生物化学与检验学分册 1996;17:145-148.
45 Dannenberg AJ,Altorki NK,Boyle Jo,et al.Cyclo-oxygenase 2;a pharmacological target for the prevention of cancer.Lancet Oncol,2001;2:544-551.
46 Brabender J,Park J,Metzger R,et al.Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.Ann Surg,2002;235:440-443.
47 Spitz M.R.,Wei Q.,Dong Q.,et al.Genetic Susceptibility to Lung Cancer:The Role of DNA Damage and Repair.Cancer Epidemiol Biomarkers Prey 2003,12:689-698.
48 孙志贤,陈惠鹏.真核细胞DNA碱基损伤及切除修复酶.国外医学分子生物学分册1993;15:120-124.
49 杨俊霞,汤为学.DNA修复机制与肿瘤耐药性.国外医学肿瘤学分册 2000;27:352-5
50 Stanton L.Gerson Clinical Relevance of MGMT in the Treatment of Cancer Journal of Clinical Oncology,2002 20(9):2388-2399.
51 Featherstone C,Jackon SP.Ku,a DNA repair Protein with multiple cellular function[J]?Mutat Res,1999,434:3-15.
52 Eriksson A,Lewensoh R.Larsson R,et al.DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity.Antieancer Res.2002.22:1787-1793.
53 李昕 李建民 杨志平 等.Bcl-xL及DNA-PKcs在ⅡB期骨肉瘤中的表达及临床意义中国骨肿瘤骨病 2005 4(1):23-25.
54 Mark R.Velangi,Elizabeth C.Matheson,Gareth J.Morgan,etal.DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma Carcinogenesis 200425(10):1795-1803.
55 Jane A.Plumb,Gordon Strathdee,Julieann Sludden,etal.Reversal of Drug Resistance in Human Tumor Xenografts by 2-Deoxy-5-azacytidine induced Demethylation of the hMLH1 Gene Promoter cancer research,2000,60:6039-6044.
56 Selvakumaran M,Pisarcik DA,Bao R,et al Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.Cancer Res,2003.63:1311-1316.
57 Elizabeth Rosenberg,Mohiuddin M.Taher,Nancy B.Kuemmerle,et al A Truncated Human Xeroderma Pigrnentosum Complementation Group A Protein Expressed from an Adenovirus Sensitizes Human Tumor Cells to Ultraviolet Light and Cisplatin Cancer Research 2001,61:764-770.
58 Sartorius UA,Krammer PH.Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cell lines.Int J Cancer,2002,97(5):584-592.
59 Rudin CM,Kozloff M,Edelman MJ,etal.Bcl-2 as a target in lung cancer.lung cancer,2003,41(suppl):S80.
60 乌英红,陈俊杰.Bax的基因结构与功能.国外医学分子生物学分册 1997;19:212-216.
61 Bennett MW,0'Connel J,0'Sullivan GC,etal.The Fas counterattack in vivo apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas Ligand expression by human esophageal carcinoma[J].J immunol,1998,160:5669-5673.
62 褚晓源,陈龙邦,王靖华非小细胞肺癌Fas/FasL基因蛋白的表达及其临床意义医学研究生学报 2003,16(2):214-217.
63 李小明,孙志贤.细胞凋亡中的关键蛋白酶-Caspase-3.国外医学分子生物学分册1999:21:6-9.
64 Ambrosini G,Adida C,Altieri DC.Anovel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med,1997,3:917-921.
65 Shin S,Sung BJ,Cho YS,et al.An anti-apoptotic protein human surviving is a direct inhibitor of caspase-3 and -7.Biochemistry.2001,40(4):1117-1123.
66 陈军,严瑞琪,汪慧民等.P53基因的生化功能和失活机理.国外医学分子生物学分册.1994;16:128-132.
67 李晋涛,刘昕,吴玉章.p53基因与DNA修复.国外医学分子生物学分册2001;23:151-153.
68 Kaelin WG Jr.The P53 gene family[J].Oncogene,1999,18(53):7701-7705.
69 司少艳,张建中.p63基因研究进展世界华人消化杂志 2003;11(5):606-609.
70 Massion PP,Taflan PM,Jamshedur Rahman SM,et al.Significance of p63 amplification and overexpression in lung cancer development and prognosis.Cancer Res,2003,63:7113-7121.
71 Kaghad M,Bonnet H,Yang A,et al.Monoallelically expressed gene related to p53 at 1p36,a region frequently deleted in neuroblastoma and other human cancers.Cell,1997,90:809-815.
72 龚永生,蔡志强,段华汛,等.p73蛋白在小细胞肺癌组织中的表达及意义.武汉大学学报(医学版),2002,23(3):199-202.
73 刘铁文 c-myc与细胞生长调控 国外医学遗传学分册 2000,23(4):223-224.
74 李奇志,张胜名,毛永荣等.非小细胞肺癌中c-myc和p73的表达及意义现代肿瘤医学 2004,12(2):83-85.
75 何英 张积仁 张健 等.C-myc异常表达与KB细胞多药耐药性的关系及其意义 中华耳鼻咽喉科杂志 2000,35(6):454-456。
76 Serrano M,Hanon J,Beach D.A new regulatory molif in cell-cycle control causing specific inhibition of Cyclin/CDK4.Nature,1993,366:704-707.
77 石红林 多肿瘤抑制基因P16及其家族的研究进展河南诊断与治疗杂志 2000 14(3):143-144.
78 张军航 马琳 刘芙蓉 等肺癌组织中p16基因mRNA表达及其临床意义中华实验外科杂志 2004,21(4):464-465.
79 Polyak K,Kato J,Solomon M,et al.p27kipl,a cyclin-CDK inhibitor;links transforming growth factor-8 and contact inhibition to cell cycle arrest.Genes Dev.1994,8:9-22.
80 谢启超 p27研究进展 国外医学肿瘤学分册 2003,30(1):48-50.
81 姜斌,王雅杰,刘宝妹P27蛋白在非小细胞肺癌中表达的预后意义 中华结核和呼吸杂志 2001,24(1):51-52.
82 David W Leung,George Cachianes,Wun-Jing Kuang,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science 1989,246:1306-1310.
83 Fontanini G,Vignati S Lucchi M etal.Neoangiogenesis and P53 protein in lung cancer:their prognostic role and their relation with VEGF expression.Br J Cancer,1997.75:1295-1301.
84 党雅梅 转移抑制基因nm23的研究进展 医学分子生物学杂志2004,1(6):373-375.
85 陈军 nm23基因与肺癌转移关系的研究进展 中国肺癌杂志2000,3(3):230-232.
86 Langton BC,Crenshaw MC,Chao LA,etal.An antigen immunologically related to the external domain of gp185 is shed from nude mouse turmors overexpressing the c-erbB-2HER-2/neuoncogene[J].Cancer Res,1991,51(10):2593-2597.
87 李洪胜,王远东,刘健雄EGFR与HER2对非小细胞肺癌的预后观察中国肿瘤临床2004,31(23):1354-1357.
88 吴曙华 蒋绍庆 段光军 HER2、HER1在非小细胞肺癌中过度表达及其临床意义肿瘤2005,25(5):462-462.
89 Kommann M.Danenberg KD,Arber N,el al.Inhibition of cyclin Dl expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.Cancer Res,1999.59:3505-3511.
90 Takasaki Y,Kaneda K,Takeuchi K,et al.Analysis of the Structure of Proteasome Proliferating Cell Nuclear Antigen(PCNA)Multiprotein Complex and Its Autoimmune Response in Lupus Patients.AnnN Y Acad Sci.2003;987:316-318.
91 肖秀英PCNA在恶性肿瘤中的研究进展 张家口医学院学报,2003,20(6):42-44.
92 Gerdes J,Li L,Schluter C,etal.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki67.Am j Pathol,1991,138(4):867-873.
93 杜洁 Pki67及其临床应用现状 华西医学 2004,19(2):322-323.
1 廖美琳,徐昌文,曹毓秀,等.2636例原发支气管肺癌手术后生存率的分析.中华肿瘤杂志,1988,10(1):34-36.
2 Chirurgische A,Thoraxklinik HG,Amalienstrasse D,et al.Principles of surgical treatment in localized non-small cell lung cancer.Lung Cancer,2001,33(Suppl 1):S3-S8.
3 Birim O,Zuydendorp HM,Maat AP,et al.Lung resection for non-small-cell lung cancer in patients older than 70:mortality,morbidity,and late survival compared with the general population.Ann Thorac Surg,2003,76(6):1796-1801.
4 刘顺寿,魏今,罗全,等.1667例肺癌外科治疗的多因素预后分析.临床医学,2003,17(1):34-36.
5 Okada M,Nishio W,Sakamoto T,et al.Evolution of surgical outcomes for nonsmall cell lung cancer:time trends in 1465 consecutive patients undergoing complete resection.Ann Thorac Surg,2004,77(6):1926-1930.
6 吴一龙,黄植藩,戎铁华,等.基于97分期的非小细胞肺癌术后分期和生存研究.中华肿瘤杂志,1999,21(5):363-365.
7 Giorgio V.Scagliotti,Roldano Fossati,Valter Torri,et al.Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage Ⅰ,Ⅱ,or ⅢA Non-Small-Cell Lung Cancer.Journal of the National Cancer Institute,2003,95(19):1453-1461.
8 Chevalier TL,Pignon JP,Bergrnan B,et al.Results of the Randomized International Adjuvant Lung Lancer Trail(IALT):ciplatin-based chemotherapy(CT)vs no CT in 1867patients with resected non-small cell lung cancer(NSCLC).Lung Cancer,2003,41(52):S3.
9 杨学宁,廖日强,吴一龙.NCCN非小细胞肺癌临床指引(2002.1版)[J].循证医学,2002,2(4):243-256.
10 C.Sofia and T.Le Chevalier.Is cisplatin still the best platinum compound in non-small-cell lung cancer?.Annals of Oncology,2002,13:1515-1517.
11 Kelly K,Crowley J,Bunn PA,etal.Randomized phase m trailof paclitaxel plus carboplatin versus vinorelbine plus cisplatin in thetreatment of patients with advanced non-small cell lung cancer:a Southwest oncology Group trial[J].J Clin Oncol,2001,19(13):3210-3218.
12 韩宝惠.晚期非小细胞肺癌化疗周期的新争议[J].中国肺癌杂志,2004,7(1):1-3.
13 廖日强,扬学宁,吴一龙。Ⅱ、ⅢA期非小细胞肺癌完全切除术后辅助治疗的价值[J]. 循证医学 2003,3(2):97-98.
14 Keller S M,Adak S,wagner H,et al.A randomized trial of Postoperative adjuvant therapy in Patients with completelyresected stage Ⅱ、ⅢA non-small cell lung cancer.Eastern cooperative oncology group[J].N Engl J Med 2000,343(17):1217-1222.
15 Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin Trials,1996,17(1):1-12.
16 Moher D,Pham B,Jones A,et al.Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analysis[J].Lancet,1998,352:609-613.
17 K Nakagawa,H Tada,A Akashi etal.Randomised study of adjuvant chemotherapy for completely resected p-stage Ⅰ-ⅢA non-small cell lung cancer.British Journal of Cancer 2006 95:817-821.
18 Jean-Yves Douillard,Rafael Rosell,Mario De Lena etal.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association [ANITA]):a randomised controlled trial.Lancet Oncol.2006 7(9):719-27.
19 Munehisa Imaizumi.Postoperative adjuvant cisplatin,vindesine,plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.Lung Cancer 2005 49:85-94
20 Timothy Winton,Robert Livingston,David Johnson,etal.Vinorelbine plus Cisplatin vs.Observation in Resected Non-Small-Cell Lung Cancer.N Engl J Med.2005352(25):2589-97.
21 Jong Ho Park,Choon-Taek Lee,Hae Won Lee,etal.Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.European Journal of Cardio-thoracic Surgery 200527:1086-1091.
22 M.Nakagawa,F.Tanaka,N.Tsubota,etal.A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer:the West Japan Study Group for Lung Cancer Surgery(WJSG)-the 4th study.Annals of Oncology 2005 16(1):75-80.
23 The International Adjuvant Lung Cancer Trial Collaborative Group.Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer.N Engl J Med.2004;350(4):351-60.
24 D.Waller,Peake,R.J.Stephens,etal.Chemotherapy for patients with non-small cell lung cancer:the surgical setting of the Big Lung Trial.Eur J Cardiothorac Surg 2004;26:173-182.
25 Harubumi Kato,Yukito Ichinose,Morio Ohta,etal.A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung.N Engl J Med.2004350(17):1713-21.
26 Strauss,GM,Herndon,J,Maddaus,MA,et al.Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer(NSCLC):report of Cancer and Leukemia Group B(CALGB)Protocol 9633.J Clin Oncol 2004;22,621-c.
27 Chiaki Endo,Yasuki Saito,Hiroshi Iwanami,etal.A randomized trial of postoperative UFT therapy in p stage Ⅰ,Ⅱ non-small cell lung cancer:North-east Japan Study Group for Lung Cancer Surgery.Lung Cancer 2003 40:181-186.
28 Tommaso CM,Vincenzo A,Vincenzo C,etal.Postoperative adjuvant therapy for stage IB non-small-cell lung cancer.Eur J Cardiothorac Surg 2001;20:378-384.
29 Hiromi Wada,Ryo Miyahara,Fumihiro Tanaka etal.Postoperative adjuvant chemotherapy with PVM(Cisplatin + Vindesine + Mitomycin C)and UFT(Uracil + Tegaful)in resected stage Ⅰ-Ⅱ NSCLC(non-small cell lung cancer):a randomized clinical trial.European Journal of Cardio-thoracic Surgery 1999;15(4):438-443.
30 付尚志 蒲萍.非小细胞肺癌术后辅助治疗疗效分析.临床肿瘤学杂志20027(1):32-34.
31 徐光川,戎铁华,林鹏.非小细胞肺癌术后辅助化疗随机研究.中华肿瘤杂志 199820(3):228-230.
32 沈德义.Ⅰ、Ⅱ期非小细胞肺癌术后辅助化疗的远期疗效。肿瘤研究与临床 19979(2):107-109.
33 Clarke M,Oxman AD,editors.Cochrane reviewers'Handbook4.1(updated june 2000).In:Review Manager(Review)[Computer program],Version 4.1.Oxford,England:the Cochrane Collaboration,2000.
34 Egger M,Smith GD,Schneider M,et al.Bias in meta-analysis detected by a simple,graphical test.BMJ 1997;315:629-634.
35 李静,王家良.系统综述的方法与原则.中华医学杂志.2001;81(1):53-55
36 刘建平.循证医学与临床实践.医学与哲学.1999;20(10):4-6.
37 Parkin DM,Pisani P,Ferla J.Global Cancer Statistics.CA cancer J Clin 1999;49(1):33-36.
1 蔡俊杰 陈源赵 菲免疫组织化学染色技术EV 二步法和LSAB法的应用比较中国组织化学与细胞化学杂志 200110(4):462-463.
2 Kononen J,Bubendorf L,Kallionieni A,et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nature Med,1998,4(7):844-847.
3 J Packeisen,E Korsching,H Herbst.etal.Demystified Tissue microarray technology.Journal of Clinical Pathology 2002;55:613-615.
4 Chih Long Liu,Wijan Prapong,Yasodha Natkunam.etal.Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays.Am J Patho 1 2002;161:1557-1565.
5 Chih Long Liu,Wijan Prapong,Yasodha Natkunam.etal.Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays.Am J Patho I 2002,161(5):1557-1565.
6 Chirurgische A,Thoraxklinik HG,Amalienstrasse D,et al.Principles of surgical treatment in localized non-small cell lung cancer.Lung Cancer,2001,33(Suppl 1):S3-S8
7 Chevalier TL,Pignon JP,Bergrnan B,et al.Results of the Randomized International Adjuvant Lung Lancer Trail(IALT):ciplatin-based chemotherapy(CT)vs no CT in 1867patients with resected non-small cell lung cancer(NSCLC).Lung Cancer,2003;41(52):3-7.
8 廖日强,扬学宁,吴一龙。Ⅱ、ⅢA期非小细胞肺癌完全切除术后辅助治疗的价值 循证医学,2003,3(2):97-98.
9 Keller S M,Adak S,wagner H,et al.A randomized trial of Postoperative adjuvant therapy in Patients with completelyresected stage Ⅱ、ⅢA non-small cell lung cancer.Eastern cooperative oncology group[J].N Engl J Med,2000,343(17):1217-1222.
10 乌英红,陈俊杰.Bax的基因结构与功能.国外医学分子生物学分册 1997;19:212-216.
11 何勇,李继良,李桃源,等.Bcl-2和Bax在非小细胞肺癌中的表达 中国肿瘤2002,11(12):738-740.
12 Ambrosini G,Adida C,Altieri DC.Anovel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med,1997,3:917-921.
13 向敏峰 刘德森 陈发龙等.非小细胞肺癌中Survivin蛋白与p63蛋白的表达及其相关性广西医科大学学报 2005,22(2):228-230.
14 Lori JG,Hanan GA,Mark W,etal.Expression of a multidrug resistance gene in human cancer.Journal of the national cancer institute 1989 81(2):116-124.
15 李波.逆转mdrl基因导致肿瘤多药耐药性的研究进展 中国普外基础与临床杂志2004,11(6):554-556.
16 Izquierdo GL,Wingaard PLJ,Flens MJ,et al.Relationship of LRP human major vault protein to in vitro and clinical resistance to anticancer drug.Cytotechnology,1996,19(3):191-197.
17 李小曼,王恩华肺耐药相关蛋白及其介导的多药耐药研究进展解剖科学进展2002,8(4):358-360.
18 Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67.J Immunol,1984,133:1710-1715.
19 杜洁.Ki-67及其临床应用现状 华西医学,2004,19(2):322-323.
20 李晋涛,刘昕,吴玉章.p53基因与DNA修复.国外医学分子生物学分册2001;23:151-153.
21 余震.肿瘤抑制基因和耐药基因在肿瘤化疗中的应用进展 浙江临床医学2004,6(8):732-734.
22 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene products.Cancer Res,1995,55:968-970.
23 Ute Wamecke-Eberz~1,Ralf Metzger~1,Futoshi Miyazono High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer Clinical Cancer Research 2004,10:3794-3799.
24 周彩存,徐妍,苏春霞.ERCC1在非小细胞肺癌中表达及其临床意义 中国癌症杂志 2006,6(8):622-625.
25 David W Leung,George Cachianes,Wun-Jing Kuang,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science 1989,246:1306-1310.
26 Fontanini G,Vignati S Lucchi M etal.Neoangiogenesis and P53 protein in lung cancer:their prognostic role and their relation with VEGF expression.Br J Cancer,1997,75:1295-1301.
1 杨纯正.肿瘤耐药研究的若干问题.中华医学杂志.2001,81(24):1475-1478
2 Enokida H,Gotanda T,Oku S,et al.Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.Jpn J Cancer Res,2002,93(9):1037-1046.
3 Nakagawa M,Enokida H,Gotanda T,et al.Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.Aktuelle Urol,2003,34(4):250-252.
4 Mirski SE,Evans CD,Almquist KC,et al.Altered topoisomerase Ⅱαin a drug-resistant small cell lung cancer cell line.Cancer Res,1993,53:4866-4873.
5 Yang LY,Trujillo JM.Biological chracterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.Cancer Res 1990;50:3218-3225.
6 程国钧,李亚里,田方,等.不同方式诱导人卵巢癌顺铂耐药细胞株的比较.中华肿瘤杂志,2001,23(7):305-308.
7 栾英姿 李力 黎丹戎等 五种耐药卵巢癌细胞株的建立以及部分耐药相关基因的表达 中华妇产科杂志 2004 39(6):403-407.
8 Bielder JL,Riehm H.Cellular resistance to actinomycin D in Chiness hamster cells in vitro:cross resistance,radioauto graphic and cytogenetic studies.Cancer Res,1970,30(4):1174-1178.
9 Uchiyama-kokubu N,Walanabe T.Establishment and characterization of adriamycinresistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.Anticancer Drugs,2001,12(9):769-777.
10 Hosking LK.Whelan RD.Shellard SA,et al.Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.Int J Cancer,1994,57(2):259-267.
11 杨纯正.肿瘤耐药研究进展.中华血液学杂志,1997,18:1-2.
12 Snow K,Jodd W.Characterization of adriamycin and amsacrine-resistant human leukaemic T cell lines.Br J Cancer,1991,63(1):17-28.
13 Iwasaki I,Sugiyama H,Kanazawa S,et al.Establishment of cisplatin-resistant variants of human neuroblastoma cell lines,TGW and GOTO,and their drug cross-resistance profiles.Cancer Chemother Pharmacol,2002,49(6):438-44.
14 Mobus VJ,Gerharz CD,Weikel W,et al.Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.Gynecol Oncol,2001,83(3):523-32.
15 陈建利,杨瑞芳,刘福生,等.卵巢上皮性癌顺铂耐药细胞株的建立及其多药耐药蛋白的表达.中华妇产科杂志,2000,35(10):617-622.
16 van Duin M,de Wit J,Odijk H,et al.Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair geneRAD10[J].Cell,1986,44:913-923.
17 Shirota Y,Stoehlmacher J,Brabender J,et al.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin an d fluorouracil chemotherapy[J].J Clin Oncol,2001,19:4298-4304.
18 Wachters FM,Wong LS,Timens W,et al.ERCC1,hRad51,and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J].Lung Cancer,2005,50(2):211-219.
19 Steven W,Johnson,James P,et al.Cisplatin and its Analogues[M].Cancer:Principles and Practice of Oncology,6th Edition,Lippincott Williams & Wilkins,USA,2001:380-382.
20 McHugh PJ,Spanswick VJ,Hartley JA.Repair of DNA interstrand crosslinks:molecular mechanisms and clinical relevance[J].Lancet Oncol,2001,2:483-490.
21 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene products[J].Cancer Res, 1995,55:968-970.
22 S.Gurubhagavatula, W zhou, S.Park, et al. Nucleotide excision repair (NER)gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis. Journal of clinical oncology, 2004 ASCO Anmial Meeting proceedings, vol 22, No145(July 15 supplement),2004:3040.
23 Zhou w, Gurubhagavatula S, Liu G, et al. Excission Repair Cross- Complementation group 1 polymorphism predicts overall survival in advance non-small cell lung cancer patients treated with platinum-base chemotherapy. Clin Cancer Res.2004, 10(15): 4939-4943.
24 Simon GR ,Sharma S,Cantor A,et al. ERCC1 expression is a predictor of survival in resected patients with non small-cell lung cancer[J]. Chest, 2005, 127: 978-983.
25 Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin induced DNA damage in human ovarian cancer cells. Anticancer Res, 2000,20(2A):645-52.
26 Seve P, Dumontet C Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005 Jan;5(1):73-88.
27 Thompson LH, Bachinske LL, Stellings RL, et al. Complementation of repair gene mutations on the hemizygous chromosome 9 in CHO: a third repair gene on human chromosome 19. Genomics, 1989,5(4):670-9.
28 van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO. Cell, 1986,44(6):913-923.
29 Chen P, Wiencke J, Aldape E, et al. Association of an ERCC1 polymorphism with adult-onset glioma.Cancer Epidemiol Biomarkers Prev, 2000, 9(8):843-847.
30 Cheng L, Sturgis EM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer, 2002, 94(2):393-97.
31 Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development lf melanoma. Cancer Res, 2000, 60(20):5612-5616.
32 Tomescu D, Kavanagh G, Ha T, et al. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis, 2001, 22(3),403-408.
33 韩为农,李虹,谢鹭等。人鼻咽与鼻咽癌cDNA阵谱中DNA修复相关基因表达差异的初步研究。中华肿瘤杂志,2002,24(2):114-117.
34 吕嘉春,吴中亮,施侣元等.核苷酸切除修复基因表达低下与肺癌的关系.中国公共卫生,2003,19(7):780-782.
35 Yu JJ,Bicher A,Ma YK,et al.Absence of evidence for allelic loss of allelic gain ERCC-1or for XPD in human ovarian cells and tissucer.Cancer Lett.2000 14:151(2):127-132.
36 Rosell R,Lord RVN,Taron M,et al.DNA repair and cisplatin ressistance in non-small-cell lung cancer.Lung Cancer 2002,38:217-227.
37 Monzo M,Rosell R,Taron M.Drug resistance in non-small cell lung cancer[J].Lung Cancer,2001,34 suppl 2:s91-94.
38 Simon GR,Sharma S,Cantor A,et al.ERCC-1 expression is a predictor of survival in resected patients with non-small lung cancer.Chest,2005,127(3):978-983.
39 黄培钰,张力,梁小曼等.晚期非小细胞肺癌组织中ERCC-1、Metallothionein、p53表达与铂类耐药性及预后的相关性分析.癌症,2004,23(7):840-850.
1 international human Genome Sequencing consortium.Finishing the euchromatic sequence of the human genome.Nature,2004.431(7011),931-945.
2 van Duin M,de Wit J,Odijk H,et al.Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair geneRAD10[J].Cell,1986,44(6):913-923.
3 Mandcl M,et al.Calcium-dependent bacteriophage DNA infection[J].Mol Biol,1970,53(1):159-162.
4 parada LF,Tabin CJ,Shih C,etal.Human EJ bladder carcinoma oncoene is homologue of harvey sarcoma virus ras gene.Natrue,1982;297(5866):474-478.
5 曾益新 主编.肿瘤学.第二版.北京:人民卫生出版社,2003,157-158.
6 Liotta LA,Steeg PS,Stetler-stevenson WG.Cancer metastasis and angiogenesis:an imbalance of positive and negative regulation.Cell 1991;64(2):327-336.
7 Steven W,Johnson,James P,et al.Cisplatin and its Analogues[M].Cancer:Principles and Practice of Oncology,6th Edition,Lippincott Williams & Wilkins,USA,2001:380-382.
8 McHugh PJ,Spanswick VJ,Hartley JA.Repair of DNA interstrand crosslinks:molecular mechanisms and clinical relevance[J].Lancet Oncol,2001,2:483-490.
9 Norgaard JM,Olesen LH,Hokland P.Changing picture of cellular drug resistance in human leukemia.Crit Rev Oncol Hematol.2004;50(1):39-49.
10 涂文升 黎丹戎 韦长元 高效液相色谱法测定肝癌耐药细胞内阿霉素的含量 中国医学文摘·肿瘤学 2005,19(2):162-163
11 Leslie EM,Deeley RG,Cole SP.Multidrug resistance proteins:role of P-glycoprotein,MRP1,MRP2,and BCRP(ABCG2)in tissue defense.Toxicol Appl Pharmacol.2005;204(3):216-37.
12 Hoffmann U,Kroemer HK.The ABC transporters MDR1 and MRP2:multiple functions in disposition of xenobiotics and drug resistance.Drug Metab Rev.2004 Oct;36(3-4):669-701.
1 Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenohabditis elegans[J].Nature,1998.391;806-811.
2 Verma NK,Dey CS.RNA-mediated gene silencing:mechanisms and its therapeutic applications[J].J ClinPharm Ther,2004,29(5):395-404.
3 Bustin SA.Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays.J Mol Endocrinol,2000;25:169-93.
4 Bustin SA.Quantification of mRNA using real-time reverse transcription PCR(RT-PCR):trends and problems.J Mol Endocrinol,2002;29:23-39.
5 Guo JQ,Lin H,Kantarjian H,et al.Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.Leukemia,2002;16:2447-53.
6 Dotsch J,Repp R,Rascher W,et al.Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas.Expert Rev Mol Diagn,2001;1:233-8.
7 Giulietti A,Overbergh L,Valckx D,et al.An overview of real-time quantitative PCR:applications to quantify cytokine gene expression.Methods,2001;25:386-401.
8 Castello R,Estelles A,Vazquez C,et al.Quantitative real-time reverse transcription PCR assay for urokinase plasminogen activator,plasminogen activator inhibitor type 1,and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.Clin Chem,2002,48(8):1288-1295.
9 Cazzaniga G,Rossi V,Biondi A.Mornitoring minimal residualdisease using chromosomal translocations in childhood acute lymphoblastic leukemia.Best Pract Res Clin Haematol,2002;15:21-35.
10 Crimwade D. The significance of minimal residual disease in pationts with t(15;17). Best Pract Res Clin Haematol, 2002;15: 137-158.
11 Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques ,1999 ;26: 112-22,124-5.
12 Elbashir SM. Lendeckel W. Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs [J].Genes Dev. 2001. 15(2): 188-200.
13 Castello R, Estelles A, Vazquez C, et al. Quantitative real-time reverse transcription PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer[J]. Clin Chem , 2002, 48(8): 1288-1295.
14 Fire A, Xu S, Montgomery MK, et al. Potent and specific interference by double-stranded RNA in Caenorhabditis elegants. Nature, 1998, 391(6669),806-811.
15 Michaela Scherr, Michael A. Morgan and Matthial Eder. Gene Silencing mediated by small interfering RNAs in mammalian cells. CurrentMedicinal Chemistry, 2003, 10(3): 245-256.
16 V. Narry Kim. RNA interference in functional genomics and medicine. J Korean Sci, 2003,18(3): 309-318.
17 Lipardi C, Wei Q, Paterson BM. RNAi as random degradative PCR. siRNA primers convent mRNA into dsRNA that are degraded to generate new siRNAs[J]Cell, 2001,107: 297.
18 Ketting RF, Haverkamp TH, VanLuenen HG, et al. Mut-7 of Celegans, required for transposon silencing and RNA interference is a homolog of Wemer syndrome helicase and RNase DE. Cell, 1999, 99: 133.
19 Dzitoyeva S, Dimitrijevic N, Manev H. Intra-abdominal injection of double-staranded RNA into anesthetized adult Drosophila triggers RNA interference in the central nervous system[J]. Mol Psychiatry, 2001, 6(6): 665.
20 Grishok A. Pasquinelli AE. Conte D. et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that Control C. elegans developmental timing[J], Cell, 2001, 106: 23.
21 Lipardi C, Wei Q. Paterson BM . RNAi as random degradative PCR. siRNA prim ers convent mRNA intodsRNA that are degraded to generatenew siRNAs[J]Cell,2001,107(3):297-307.
22 Silen T,Fleenor J,et al.On the roleof RNA amplification in dsRNA-triggered gene silencing[J].Cell,2002,107(4):465-467.
23 Nishikura K.A short primer onRNAi:RNA-directed RNA poly-merase acts as a key catalyst[J].Cell,2001,107(4):415-418.
24 Yukihide T,Phillip DZ。Perspective:machines for RNAi[J].Genes Dev.2005.19(6):517-529.
25 Guangchao Sui,Christina Soohoo,El Bachir Affar,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cell.PANS,2002,99(8):5515-5520.
26 Hiroaki Kawasaki and Kazunari Taira.Short hairpin type of dsRNAs thatare controlled by tRNAval promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells.Nucleic Acids Research,2003,31(2):700-707.
27 Sledz CA,Holko M,de Veer MJ,et al.Activation of the interferon system by short-interfering RNAs.Nature Cell Biol.2003,5:834-9.
28 Bridge AJ,Pebernard S,Ducraux A,et al.Induction of an interferon response by RNAi vectors in maimalian cells.Nature Genet,2003,34:263-4.
29 Jackson AL,Bartz SR,Scheher J,et al.Expression profiling reveals off-target gene regulation by RNAi.Nature Biotechnol,2003,21:635-7.
30 Scacheri PC,Rozenblatt-Rosen O,Caplen NJ,et al.Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.Proc Natl Acad Sci USA,2004,101:1892-7.
2 Parkin DM.Global cancer statistics in the year of 2000[J].Lancet Oncol,2001,2(9):543-552.
3 周际昌,主编.实用肿瘤内科学.北京:人民卫生出版社,2003.543-552.
4 廖美琳.周允中.严德钧等Ⅰ期NSCLC术后辅助治疗的研究.中国癌症杂志,1998.8:66-69.
5 Munehisa Imaizumi.Postoperative adjuvant cisplatin,vindesine,plus uracil tegafur chemotherapy increased survival of patients with completely resected p-stage Ⅰ non-small cell lung cancer.Lung Cancer(2005)49,85-94.
6 Socinski MA,Kies M,Schell MJ.et al Duration of therapy in stage ⅢB non small cell Lung cancer(NSCLC)a multi-institutional phase Ⅱtrial,Proc Am SOC clin Oncol.2001,20:309A.
7 Smith JE,Brien MER,Talboe DC.et al.Duration of Chemotherapy in Aduvanced Non-Small-Cell-Lung Cancer:A Randomized Trial of Three Verse Six Course of Mitimycin,Vinblastine.and Cisplatin.J Clin()ncol,2001,19(3):1336-1343.
8 Wada H,Tanaka F,Hitomi S,et al.Postoperative adjuvant chemotherapy for non-small-cell lung cancer.West Japan Study Group for Lung Cancer Surgery.The Japan Lung Cancer Research Group on Post surgical Adjuvant Chemotherapy[J].Oncology (Huntingt).1997,11(9 Suppl 10):98-102.
9 Endo C,Saito Y,wanami H,et al.A randomized trial of postoperative UFT therapy in P stage Ⅰ.Ⅱ non-small-cell lung cancer:North-east Japan Study Group for Lung Cancer Surgery[J].Lung Cancer,2003,40(2):181-186.
10 Kato H,Tsuboi M,Ohta M,et al.A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage Ⅰ(T1NOM0,T2N0M0)adenocarcinoma of the lung[J].Proc Am Soc Clin Oncol.2003,23:2498a.
11 吴一龙,廖美琳,周清华 非小细胞肺癌术后辅助治疗共识 循证医学2004,4(4):256-238.
12 吴一龙.肿癌多学科综合治疗的理论与实践[M].北京:人民卫生出版社,2000.195-198.
13 Keller,SM,Adak,S,Wagner,H,et al A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or Ⅲa non-small-cell lung cancer.N Engl J Med 2000;343,1217-1222.
14 Wolf M,Mailer H H,Seifart U,et al.Randomized phase Ⅲ trial of adjuvant radiotherapy vs adjuvant chemotherapy followed by radiotherapy in patients with N2 positive non small cell lung cancer(NSCLC).Proc Am Soc Clin Oncol.2001,20:1242a
15 Ichinose Y,Taga H,Koike T,etal.Chemotherapy in patients with completely resected stage Ⅲa N2 non small cell lung cancer:japan clinical oncology group(JCOG)trial[A].Proc Am Soc Clin Oncol.2001,20:1241a.
16 Scagliotti GV,Fossati R,Torri V,etal.Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ,Ⅱ,or Ⅲa Non-Small Cell Lung Cancer.J Natl Cancer Inst,2003,95(19):1453-1461.
17 The International Adjuvant Lung Cancer Trial Collaborative Group.Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer.N Engl J Med.2004;350(4):351-60.
18 Winton T,Livingston R,Johnson D,etal.A prospective randomized trial of ajuvant vinorelbine(VIN)and cisplatin(CIS)in completely resected stage ⅠB and Ⅱ non-small cell lung cancer(NSCLC)Intergroup JBR 10[C].Proc Am Soc Clin Oncol,2004,23(suppl):17.7018a.
19 Strauss,GM,Herndon,J,Maddaus,MA,et al.Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage ⅠB non-small cell lung cancer(NSCLC):report of Cancer and Leukemia Group B(CALGB)Protocol 9633.J Clin Oncol 2004;22,621-c.
20 non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J].BMJ,1995,311:899-909.
21 廖日强,吴一龙,杨学宁,等。非小细胞肺癌完全切除术后含铂化疗方案的累积meta分析.循证医学,2003,3(4):196-203.
22 Douglas West,Alan JB,Joel Dunning.Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival.Interact Cardio Vasc Thorac Surg 2006;5:488-492.
23 Desmond N.Carney Lung Cancer-Time to Move on from Chemotherapy The new England journal of medicain 2002,346:126-128.
24 Luqmani YA.Mechanisms of drug resistance in cancer chemotherapy.Med Princ Pract.2005;Suppl 1:35-48.
25 Chintamani,Singh JP,Mittal MK,et al.Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study.World J Surg Oncol.2005,3:61-67.
26 Gan HZ,Zhang GZ,Zhao JS,et al.Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.Chin Med J(Engl).2005;118(11):893-902.
27 Kong JX,Song Q,Liu YP,et al.Inhibition of multidrug resistance gene 1 expression in glioma by antisense oligodeoxynucleotides。Zhongguo Yi Xue Ke Xue Yuan Xue Bao.2005 27(2):211-215.
28 Xiang Y,Li L,Tian F,Yang XY,et al.Improving P-gp expression in human mononuclear cells in vitro transfected by multidrug resistance-1 mRNA.Chin Med Sci J.2005;20(1):48-50.
29 孔肇路,金一尊.多药耐药相关蛋白的生物学特性与作用机制的研究进展.中国癌症杂志 2001;11:375-378.
30 Leah C.Young,Barbara G.Campling,Susan P.C.Cole,et al Multidrug Resistance Proteins MRP3,MRP1,and MRP2 in Lung Cancer Correlation of Protein Levels with Drug Response and Messenger RNA Levels Clinical Cancer Research 2001,7:1798-1804.
31 Z.P.Lin,D.R.Johnson,R.A.Finch,et al Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts Molecular Cancer Therapeutic,2002,1(12):1105-1114.
32 Izquierdo GL,Wingaard PLJ,Flens MJ,et al.Relationship of LRP human major vault protein to in vitro and clinical resistance to anticancer drug.Cytotechnology,1996,19(3):191-197
33 吕梅君,王洁,易祥华,等.肺癌耐药蛋白在非小细胞肺癌中的表达与临床相关性 研究[J].中华结核和呼吸杂志,2001,24(8):458-459.
34 Boutonnat J,Bonnefoix T,Mousseau,et al.Coexpression of multidrug resistance involve protein:a flow cytometric analysis[J].AnticancerRes,1998,18(4):2993-2999.
35 Ross DD,Yasng W,Abruzzo LV,et al.A typical multidrug resistance:breastcancer resistance protein messenger RNA expression in mitoxantrone-selected ovarian tumor cell line.J Natl Cancer Inst,1999,91:429.
36 Schellens JH,Maliepaard M,Scheper RJ,et al.Transport of topoisomerase I inhibitors by the breast cancer resistance protein.Potential clinical implications.Ann N Y Acad Sci 2000;922:188-94.
37 尚世丽,刘云鹏,于秉治.蛋白激酶C与P-糖蛋白介导的肿瘤多药耐药.国外医学药学分册.2000;27:5-7.
38 Sonnemann J.Gekeler V,Ahlbrecht K,et al.Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitizes A549 lung cancer cells to vincristine and paclitaxel.Cancer Lett,2004,29(2):177-185.
39 Ding L,Wang H,Lang W,et al.Protein 15 kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway.J Biol Chem,2002,277 16(38):35305-35313.
40 Kigawa J,Takahashi M,Minagawa Y,et al.Topoisomerase-Ⅰ activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.Int J Cancer 1999 Oct 22;84(5):521-524.
41 Yanase K,Sugimoto Y,Andoh T,et al.Retroviral expression of a mutant(Gly-533)human DNA topoisomerase Ⅰ cDNA confers a dominant form of camptothecin resistance.Int J Cancer 1999 Mar 31;81(1):134-40.
42 Boutonnat J,Bonnefoix T,Mousseau,et al.Coexpression of multidrug resistance involve protein:a flow cytometric analysis[J].Anticancer Res,1998,18(4):2993-2999.
43 李颢,徐健.谷胱甘肽-S-转移酶与白血病耐药.国外医学肿瘤学分册.1999;26:184-185.
44 周清,薛亚梅,张治.谷胱甘肽S转移酶与肺癌关系若干研究进展.国外医学临床生物化学与检验学分册 1996;17:145-148.
45 Dannenberg AJ,Altorki NK,Boyle Jo,et al.Cyclo-oxygenase 2;a pharmacological target for the prevention of cancer.Lancet Oncol,2001;2:544-551.
46 Brabender J,Park J,Metzger R,et al.Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.Ann Surg,2002;235:440-443.
47 Spitz M.R.,Wei Q.,Dong Q.,et al.Genetic Susceptibility to Lung Cancer:The Role of DNA Damage and Repair.Cancer Epidemiol Biomarkers Prey 2003,12:689-698.
48 孙志贤,陈惠鹏.真核细胞DNA碱基损伤及切除修复酶.国外医学分子生物学分册1993;15:120-124.
49 杨俊霞,汤为学.DNA修复机制与肿瘤耐药性.国外医学肿瘤学分册 2000;27:352-5
50 Stanton L.Gerson Clinical Relevance of MGMT in the Treatment of Cancer Journal of Clinical Oncology,2002 20(9):2388-2399.
51 Featherstone C,Jackon SP.Ku,a DNA repair Protein with multiple cellular function[J]?Mutat Res,1999,434:3-15.
52 Eriksson A,Lewensoh R.Larsson R,et al.DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity.Antieancer Res.2002.22:1787-1793.
53 李昕 李建民 杨志平 等.Bcl-xL及DNA-PKcs在ⅡB期骨肉瘤中的表达及临床意义中国骨肿瘤骨病 2005 4(1):23-25.
54 Mark R.Velangi,Elizabeth C.Matheson,Gareth J.Morgan,etal.DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma Carcinogenesis 200425(10):1795-1803.
55 Jane A.Plumb,Gordon Strathdee,Julieann Sludden,etal.Reversal of Drug Resistance in Human Tumor Xenografts by 2-Deoxy-5-azacytidine induced Demethylation of the hMLH1 Gene Promoter cancer research,2000,60:6039-6044.
56 Selvakumaran M,Pisarcik DA,Bao R,et al Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.Cancer Res,2003.63:1311-1316.
57 Elizabeth Rosenberg,Mohiuddin M.Taher,Nancy B.Kuemmerle,et al A Truncated Human Xeroderma Pigrnentosum Complementation Group A Protein Expressed from an Adenovirus Sensitizes Human Tumor Cells to Ultraviolet Light and Cisplatin Cancer Research 2001,61:764-770.
58 Sartorius UA,Krammer PH.Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cell lines.Int J Cancer,2002,97(5):584-592.
59 Rudin CM,Kozloff M,Edelman MJ,etal.Bcl-2 as a target in lung cancer.lung cancer,2003,41(suppl):S80.
60 乌英红,陈俊杰.Bax的基因结构与功能.国外医学分子生物学分册 1997;19:212-216.
61 Bennett MW,0'Connel J,0'Sullivan GC,etal.The Fas counterattack in vivo apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas Ligand expression by human esophageal carcinoma[J].J immunol,1998,160:5669-5673.
62 褚晓源,陈龙邦,王靖华非小细胞肺癌Fas/FasL基因蛋白的表达及其临床意义医学研究生学报 2003,16(2):214-217.
63 李小明,孙志贤.细胞凋亡中的关键蛋白酶-Caspase-3.国外医学分子生物学分册1999:21:6-9.
64 Ambrosini G,Adida C,Altieri DC.Anovel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med,1997,3:917-921.
65 Shin S,Sung BJ,Cho YS,et al.An anti-apoptotic protein human surviving is a direct inhibitor of caspase-3 and -7.Biochemistry.2001,40(4):1117-1123.
66 陈军,严瑞琪,汪慧民等.P53基因的生化功能和失活机理.国外医学分子生物学分册.1994;16:128-132.
67 李晋涛,刘昕,吴玉章.p53基因与DNA修复.国外医学分子生物学分册2001;23:151-153.
68 Kaelin WG Jr.The P53 gene family[J].Oncogene,1999,18(53):7701-7705.
69 司少艳,张建中.p63基因研究进展世界华人消化杂志 2003;11(5):606-609.
70 Massion PP,Taflan PM,Jamshedur Rahman SM,et al.Significance of p63 amplification and overexpression in lung cancer development and prognosis.Cancer Res,2003,63:7113-7121.
71 Kaghad M,Bonnet H,Yang A,et al.Monoallelically expressed gene related to p53 at 1p36,a region frequently deleted in neuroblastoma and other human cancers.Cell,1997,90:809-815.
72 龚永生,蔡志强,段华汛,等.p73蛋白在小细胞肺癌组织中的表达及意义.武汉大学学报(医学版),2002,23(3):199-202.
73 刘铁文 c-myc与细胞生长调控 国外医学遗传学分册 2000,23(4):223-224.
74 李奇志,张胜名,毛永荣等.非小细胞肺癌中c-myc和p73的表达及意义现代肿瘤医学 2004,12(2):83-85.
75 何英 张积仁 张健 等.C-myc异常表达与KB细胞多药耐药性的关系及其意义 中华耳鼻咽喉科杂志 2000,35(6):454-456。
76 Serrano M,Hanon J,Beach D.A new regulatory molif in cell-cycle control causing specific inhibition of Cyclin/CDK4.Nature,1993,366:704-707.
77 石红林 多肿瘤抑制基因P16及其家族的研究进展河南诊断与治疗杂志 2000 14(3):143-144.
78 张军航 马琳 刘芙蓉 等肺癌组织中p16基因mRNA表达及其临床意义中华实验外科杂志 2004,21(4):464-465.
79 Polyak K,Kato J,Solomon M,et al.p27kipl,a cyclin-CDK inhibitor;links transforming growth factor-8 and contact inhibition to cell cycle arrest.Genes Dev.1994,8:9-22.
80 谢启超 p27研究进展 国外医学肿瘤学分册 2003,30(1):48-50.
81 姜斌,王雅杰,刘宝妹P27蛋白在非小细胞肺癌中表达的预后意义 中华结核和呼吸杂志 2001,24(1):51-52.
82 David W Leung,George Cachianes,Wun-Jing Kuang,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science 1989,246:1306-1310.
83 Fontanini G,Vignati S Lucchi M etal.Neoangiogenesis and P53 protein in lung cancer:their prognostic role and their relation with VEGF expression.Br J Cancer,1997.75:1295-1301.
84 党雅梅 转移抑制基因nm23的研究进展 医学分子生物学杂志2004,1(6):373-375.
85 陈军 nm23基因与肺癌转移关系的研究进展 中国肺癌杂志2000,3(3):230-232.
86 Langton BC,Crenshaw MC,Chao LA,etal.An antigen immunologically related to the external domain of gp185 is shed from nude mouse turmors overexpressing the c-erbB-2HER-2/neuoncogene[J].Cancer Res,1991,51(10):2593-2597.
87 李洪胜,王远东,刘健雄EGFR与HER2对非小细胞肺癌的预后观察中国肿瘤临床2004,31(23):1354-1357.
88 吴曙华 蒋绍庆 段光军 HER2、HER1在非小细胞肺癌中过度表达及其临床意义肿瘤2005,25(5):462-462.
89 Kommann M.Danenberg KD,Arber N,el al.Inhibition of cyclin Dl expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.Cancer Res,1999.59:3505-3511.
90 Takasaki Y,Kaneda K,Takeuchi K,et al.Analysis of the Structure of Proteasome Proliferating Cell Nuclear Antigen(PCNA)Multiprotein Complex and Its Autoimmune Response in Lupus Patients.AnnN Y Acad Sci.2003;987:316-318.
91 肖秀英PCNA在恶性肿瘤中的研究进展 张家口医学院学报,2003,20(6):42-44.
92 Gerdes J,Li L,Schluter C,etal.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki67.Am j Pathol,1991,138(4):867-873.
93 杜洁 Pki67及其临床应用现状 华西医学 2004,19(2):322-323.
1 廖美琳,徐昌文,曹毓秀,等.2636例原发支气管肺癌手术后生存率的分析.中华肿瘤杂志,1988,10(1):34-36.
2 Chirurgische A,Thoraxklinik HG,Amalienstrasse D,et al.Principles of surgical treatment in localized non-small cell lung cancer.Lung Cancer,2001,33(Suppl 1):S3-S8.
3 Birim O,Zuydendorp HM,Maat AP,et al.Lung resection for non-small-cell lung cancer in patients older than 70:mortality,morbidity,and late survival compared with the general population.Ann Thorac Surg,2003,76(6):1796-1801.
4 刘顺寿,魏今,罗全,等.1667例肺癌外科治疗的多因素预后分析.临床医学,2003,17(1):34-36.
5 Okada M,Nishio W,Sakamoto T,et al.Evolution of surgical outcomes for nonsmall cell lung cancer:time trends in 1465 consecutive patients undergoing complete resection.Ann Thorac Surg,2004,77(6):1926-1930.
6 吴一龙,黄植藩,戎铁华,等.基于97分期的非小细胞肺癌术后分期和生存研究.中华肿瘤杂志,1999,21(5):363-365.
7 Giorgio V.Scagliotti,Roldano Fossati,Valter Torri,et al.Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage Ⅰ,Ⅱ,or ⅢA Non-Small-Cell Lung Cancer.Journal of the National Cancer Institute,2003,95(19):1453-1461.
8 Chevalier TL,Pignon JP,Bergrnan B,et al.Results of the Randomized International Adjuvant Lung Lancer Trail(IALT):ciplatin-based chemotherapy(CT)vs no CT in 1867patients with resected non-small cell lung cancer(NSCLC).Lung Cancer,2003,41(52):S3.
9 杨学宁,廖日强,吴一龙.NCCN非小细胞肺癌临床指引(2002.1版)[J].循证医学,2002,2(4):243-256.
10 C.Sofia and T.Le Chevalier.Is cisplatin still the best platinum compound in non-small-cell lung cancer?.Annals of Oncology,2002,13:1515-1517.
11 Kelly K,Crowley J,Bunn PA,etal.Randomized phase m trailof paclitaxel plus carboplatin versus vinorelbine plus cisplatin in thetreatment of patients with advanced non-small cell lung cancer:a Southwest oncology Group trial[J].J Clin Oncol,2001,19(13):3210-3218.
12 韩宝惠.晚期非小细胞肺癌化疗周期的新争议[J].中国肺癌杂志,2004,7(1):1-3.
13 廖日强,扬学宁,吴一龙。Ⅱ、ⅢA期非小细胞肺癌完全切除术后辅助治疗的价值[J]. 循证医学 2003,3(2):97-98.
14 Keller S M,Adak S,wagner H,et al.A randomized trial of Postoperative adjuvant therapy in Patients with completelyresected stage Ⅱ、ⅢA non-small cell lung cancer.Eastern cooperative oncology group[J].N Engl J Med 2000,343(17):1217-1222.
15 Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin Trials,1996,17(1):1-12.
16 Moher D,Pham B,Jones A,et al.Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analysis[J].Lancet,1998,352:609-613.
17 K Nakagawa,H Tada,A Akashi etal.Randomised study of adjuvant chemotherapy for completely resected p-stage Ⅰ-ⅢA non-small cell lung cancer.British Journal of Cancer 2006 95:817-821.
18 Jean-Yves Douillard,Rafael Rosell,Mario De Lena etal.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association [ANITA]):a randomised controlled trial.Lancet Oncol.2006 7(9):719-27.
19 Munehisa Imaizumi.Postoperative adjuvant cisplatin,vindesine,plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.Lung Cancer 2005 49:85-94
20 Timothy Winton,Robert Livingston,David Johnson,etal.Vinorelbine plus Cisplatin vs.Observation in Resected Non-Small-Cell Lung Cancer.N Engl J Med.2005352(25):2589-97.
21 Jong Ho Park,Choon-Taek Lee,Hae Won Lee,etal.Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.European Journal of Cardio-thoracic Surgery 200527:1086-1091.
22 M.Nakagawa,F.Tanaka,N.Tsubota,etal.A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer:the West Japan Study Group for Lung Cancer Surgery(WJSG)-the 4th study.Annals of Oncology 2005 16(1):75-80.
23 The International Adjuvant Lung Cancer Trial Collaborative Group.Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer.N Engl J Med.2004;350(4):351-60.
24 D.Waller,Peake,R.J.Stephens,etal.Chemotherapy for patients with non-small cell lung cancer:the surgical setting of the Big Lung Trial.Eur J Cardiothorac Surg 2004;26:173-182.
25 Harubumi Kato,Yukito Ichinose,Morio Ohta,etal.A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung.N Engl J Med.2004350(17):1713-21.
26 Strauss,GM,Herndon,J,Maddaus,MA,et al.Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer(NSCLC):report of Cancer and Leukemia Group B(CALGB)Protocol 9633.J Clin Oncol 2004;22,621-c.
27 Chiaki Endo,Yasuki Saito,Hiroshi Iwanami,etal.A randomized trial of postoperative UFT therapy in p stage Ⅰ,Ⅱ non-small cell lung cancer:North-east Japan Study Group for Lung Cancer Surgery.Lung Cancer 2003 40:181-186.
28 Tommaso CM,Vincenzo A,Vincenzo C,etal.Postoperative adjuvant therapy for stage IB non-small-cell lung cancer.Eur J Cardiothorac Surg 2001;20:378-384.
29 Hiromi Wada,Ryo Miyahara,Fumihiro Tanaka etal.Postoperative adjuvant chemotherapy with PVM(Cisplatin + Vindesine + Mitomycin C)and UFT(Uracil + Tegaful)in resected stage Ⅰ-Ⅱ NSCLC(non-small cell lung cancer):a randomized clinical trial.European Journal of Cardio-thoracic Surgery 1999;15(4):438-443.
30 付尚志 蒲萍.非小细胞肺癌术后辅助治疗疗效分析.临床肿瘤学杂志20027(1):32-34.
31 徐光川,戎铁华,林鹏.非小细胞肺癌术后辅助化疗随机研究.中华肿瘤杂志 199820(3):228-230.
32 沈德义.Ⅰ、Ⅱ期非小细胞肺癌术后辅助化疗的远期疗效。肿瘤研究与临床 19979(2):107-109.
33 Clarke M,Oxman AD,editors.Cochrane reviewers'Handbook4.1(updated june 2000).In:Review Manager(Review)[Computer program],Version 4.1.Oxford,England:the Cochrane Collaboration,2000.
34 Egger M,Smith GD,Schneider M,et al.Bias in meta-analysis detected by a simple,graphical test.BMJ 1997;315:629-634.
35 李静,王家良.系统综述的方法与原则.中华医学杂志.2001;81(1):53-55
36 刘建平.循证医学与临床实践.医学与哲学.1999;20(10):4-6.
37 Parkin DM,Pisani P,Ferla J.Global Cancer Statistics.CA cancer J Clin 1999;49(1):33-36.
1 蔡俊杰 陈源赵 菲免疫组织化学染色技术EV 二步法和LSAB法的应用比较中国组织化学与细胞化学杂志 200110(4):462-463.
2 Kononen J,Bubendorf L,Kallionieni A,et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nature Med,1998,4(7):844-847.
3 J Packeisen,E Korsching,H Herbst.etal.Demystified Tissue microarray technology.Journal of Clinical Pathology 2002;55:613-615.
4 Chih Long Liu,Wijan Prapong,Yasodha Natkunam.etal.Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays.Am J Patho 1 2002;161:1557-1565.
5 Chih Long Liu,Wijan Prapong,Yasodha Natkunam.etal.Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays.Am J Patho I 2002,161(5):1557-1565.
6 Chirurgische A,Thoraxklinik HG,Amalienstrasse D,et al.Principles of surgical treatment in localized non-small cell lung cancer.Lung Cancer,2001,33(Suppl 1):S3-S8
7 Chevalier TL,Pignon JP,Bergrnan B,et al.Results of the Randomized International Adjuvant Lung Lancer Trail(IALT):ciplatin-based chemotherapy(CT)vs no CT in 1867patients with resected non-small cell lung cancer(NSCLC).Lung Cancer,2003;41(52):3-7.
8 廖日强,扬学宁,吴一龙。Ⅱ、ⅢA期非小细胞肺癌完全切除术后辅助治疗的价值 循证医学,2003,3(2):97-98.
9 Keller S M,Adak S,wagner H,et al.A randomized trial of Postoperative adjuvant therapy in Patients with completelyresected stage Ⅱ、ⅢA non-small cell lung cancer.Eastern cooperative oncology group[J].N Engl J Med,2000,343(17):1217-1222.
10 乌英红,陈俊杰.Bax的基因结构与功能.国外医学分子生物学分册 1997;19:212-216.
11 何勇,李继良,李桃源,等.Bcl-2和Bax在非小细胞肺癌中的表达 中国肿瘤2002,11(12):738-740.
12 Ambrosini G,Adida C,Altieri DC.Anovel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med,1997,3:917-921.
13 向敏峰 刘德森 陈发龙等.非小细胞肺癌中Survivin蛋白与p63蛋白的表达及其相关性广西医科大学学报 2005,22(2):228-230.
14 Lori JG,Hanan GA,Mark W,etal.Expression of a multidrug resistance gene in human cancer.Journal of the national cancer institute 1989 81(2):116-124.
15 李波.逆转mdrl基因导致肿瘤多药耐药性的研究进展 中国普外基础与临床杂志2004,11(6):554-556.
16 Izquierdo GL,Wingaard PLJ,Flens MJ,et al.Relationship of LRP human major vault protein to in vitro and clinical resistance to anticancer drug.Cytotechnology,1996,19(3):191-197.
17 李小曼,王恩华肺耐药相关蛋白及其介导的多药耐药研究进展解剖科学进展2002,8(4):358-360.
18 Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67.J Immunol,1984,133:1710-1715.
19 杜洁.Ki-67及其临床应用现状 华西医学,2004,19(2):322-323.
20 李晋涛,刘昕,吴玉章.p53基因与DNA修复.国外医学分子生物学分册2001;23:151-153.
21 余震.肿瘤抑制基因和耐药基因在肿瘤化疗中的应用进展 浙江临床医学2004,6(8):732-734.
22 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene products.Cancer Res,1995,55:968-970.
23 Ute Wamecke-Eberz~1,Ralf Metzger~1,Futoshi Miyazono High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer Clinical Cancer Research 2004,10:3794-3799.
24 周彩存,徐妍,苏春霞.ERCC1在非小细胞肺癌中表达及其临床意义 中国癌症杂志 2006,6(8):622-625.
25 David W Leung,George Cachianes,Wun-Jing Kuang,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science 1989,246:1306-1310.
26 Fontanini G,Vignati S Lucchi M etal.Neoangiogenesis and P53 protein in lung cancer:their prognostic role and their relation with VEGF expression.Br J Cancer,1997,75:1295-1301.
1 杨纯正.肿瘤耐药研究的若干问题.中华医学杂志.2001,81(24):1475-1478
2 Enokida H,Gotanda T,Oku S,et al.Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.Jpn J Cancer Res,2002,93(9):1037-1046.
3 Nakagawa M,Enokida H,Gotanda T,et al.Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.Aktuelle Urol,2003,34(4):250-252.
4 Mirski SE,Evans CD,Almquist KC,et al.Altered topoisomerase Ⅱαin a drug-resistant small cell lung cancer cell line.Cancer Res,1993,53:4866-4873.
5 Yang LY,Trujillo JM.Biological chracterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.Cancer Res 1990;50:3218-3225.
6 程国钧,李亚里,田方,等.不同方式诱导人卵巢癌顺铂耐药细胞株的比较.中华肿瘤杂志,2001,23(7):305-308.
7 栾英姿 李力 黎丹戎等 五种耐药卵巢癌细胞株的建立以及部分耐药相关基因的表达 中华妇产科杂志 2004 39(6):403-407.
8 Bielder JL,Riehm H.Cellular resistance to actinomycin D in Chiness hamster cells in vitro:cross resistance,radioauto graphic and cytogenetic studies.Cancer Res,1970,30(4):1174-1178.
9 Uchiyama-kokubu N,Walanabe T.Establishment and characterization of adriamycinresistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.Anticancer Drugs,2001,12(9):769-777.
10 Hosking LK.Whelan RD.Shellard SA,et al.Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.Int J Cancer,1994,57(2):259-267.
11 杨纯正.肿瘤耐药研究进展.中华血液学杂志,1997,18:1-2.
12 Snow K,Jodd W.Characterization of adriamycin and amsacrine-resistant human leukaemic T cell lines.Br J Cancer,1991,63(1):17-28.
13 Iwasaki I,Sugiyama H,Kanazawa S,et al.Establishment of cisplatin-resistant variants of human neuroblastoma cell lines,TGW and GOTO,and their drug cross-resistance profiles.Cancer Chemother Pharmacol,2002,49(6):438-44.
14 Mobus VJ,Gerharz CD,Weikel W,et al.Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.Gynecol Oncol,2001,83(3):523-32.
15 陈建利,杨瑞芳,刘福生,等.卵巢上皮性癌顺铂耐药细胞株的建立及其多药耐药蛋白的表达.中华妇产科杂志,2000,35(10):617-622.
16 van Duin M,de Wit J,Odijk H,et al.Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair geneRAD10[J].Cell,1986,44:913-923.
17 Shirota Y,Stoehlmacher J,Brabender J,et al.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin an d fluorouracil chemotherapy[J].J Clin Oncol,2001,19:4298-4304.
18 Wachters FM,Wong LS,Timens W,et al.ERCC1,hRad51,and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J].Lung Cancer,2005,50(2):211-219.
19 Steven W,Johnson,James P,et al.Cisplatin and its Analogues[M].Cancer:Principles and Practice of Oncology,6th Edition,Lippincott Williams & Wilkins,USA,2001:380-382.
20 McHugh PJ,Spanswick VJ,Hartley JA.Repair of DNA interstrand crosslinks:molecular mechanisms and clinical relevance[J].Lancet Oncol,2001,2:483-490.
21 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene products[J].Cancer Res, 1995,55:968-970.
22 S.Gurubhagavatula, W zhou, S.Park, et al. Nucleotide excision repair (NER)gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis. Journal of clinical oncology, 2004 ASCO Anmial Meeting proceedings, vol 22, No145(July 15 supplement),2004:3040.
23 Zhou w, Gurubhagavatula S, Liu G, et al. Excission Repair Cross- Complementation group 1 polymorphism predicts overall survival in advance non-small cell lung cancer patients treated with platinum-base chemotherapy. Clin Cancer Res.2004, 10(15): 4939-4943.
24 Simon GR ,Sharma S,Cantor A,et al. ERCC1 expression is a predictor of survival in resected patients with non small-cell lung cancer[J]. Chest, 2005, 127: 978-983.
25 Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin induced DNA damage in human ovarian cancer cells. Anticancer Res, 2000,20(2A):645-52.
26 Seve P, Dumontet C Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005 Jan;5(1):73-88.
27 Thompson LH, Bachinske LL, Stellings RL, et al. Complementation of repair gene mutations on the hemizygous chromosome 9 in CHO: a third repair gene on human chromosome 19. Genomics, 1989,5(4):670-9.
28 van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO. Cell, 1986,44(6):913-923.
29 Chen P, Wiencke J, Aldape E, et al. Association of an ERCC1 polymorphism with adult-onset glioma.Cancer Epidemiol Biomarkers Prev, 2000, 9(8):843-847.
30 Cheng L, Sturgis EM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer, 2002, 94(2):393-97.
31 Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development lf melanoma. Cancer Res, 2000, 60(20):5612-5616.
32 Tomescu D, Kavanagh G, Ha T, et al. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis, 2001, 22(3),403-408.
33 韩为农,李虹,谢鹭等。人鼻咽与鼻咽癌cDNA阵谱中DNA修复相关基因表达差异的初步研究。中华肿瘤杂志,2002,24(2):114-117.
34 吕嘉春,吴中亮,施侣元等.核苷酸切除修复基因表达低下与肺癌的关系.中国公共卫生,2003,19(7):780-782.
35 Yu JJ,Bicher A,Ma YK,et al.Absence of evidence for allelic loss of allelic gain ERCC-1or for XPD in human ovarian cells and tissucer.Cancer Lett.2000 14:151(2):127-132.
36 Rosell R,Lord RVN,Taron M,et al.DNA repair and cisplatin ressistance in non-small-cell lung cancer.Lung Cancer 2002,38:217-227.
37 Monzo M,Rosell R,Taron M.Drug resistance in non-small cell lung cancer[J].Lung Cancer,2001,34 suppl 2:s91-94.
38 Simon GR,Sharma S,Cantor A,et al.ERCC-1 expression is a predictor of survival in resected patients with non-small lung cancer.Chest,2005,127(3):978-983.
39 黄培钰,张力,梁小曼等.晚期非小细胞肺癌组织中ERCC-1、Metallothionein、p53表达与铂类耐药性及预后的相关性分析.癌症,2004,23(7):840-850.
1 international human Genome Sequencing consortium.Finishing the euchromatic sequence of the human genome.Nature,2004.431(7011),931-945.
2 van Duin M,de Wit J,Odijk H,et al.Molecular characterization of the human excision repair gene ERCC-1:cDNA cloning and amino acid homology with the yeast DNA repair geneRAD10[J].Cell,1986,44(6):913-923.
3 Mandcl M,et al.Calcium-dependent bacteriophage DNA infection[J].Mol Biol,1970,53(1):159-162.
4 parada LF,Tabin CJ,Shih C,etal.Human EJ bladder carcinoma oncoene is homologue of harvey sarcoma virus ras gene.Natrue,1982;297(5866):474-478.
5 曾益新 主编.肿瘤学.第二版.北京:人民卫生出版社,2003,157-158.
6 Liotta LA,Steeg PS,Stetler-stevenson WG.Cancer metastasis and angiogenesis:an imbalance of positive and negative regulation.Cell 1991;64(2):327-336.
7 Steven W,Johnson,James P,et al.Cisplatin and its Analogues[M].Cancer:Principles and Practice of Oncology,6th Edition,Lippincott Williams & Wilkins,USA,2001:380-382.
8 McHugh PJ,Spanswick VJ,Hartley JA.Repair of DNA interstrand crosslinks:molecular mechanisms and clinical relevance[J].Lancet Oncol,2001,2:483-490.
9 Norgaard JM,Olesen LH,Hokland P.Changing picture of cellular drug resistance in human leukemia.Crit Rev Oncol Hematol.2004;50(1):39-49.
10 涂文升 黎丹戎 韦长元 高效液相色谱法测定肝癌耐药细胞内阿霉素的含量 中国医学文摘·肿瘤学 2005,19(2):162-163
11 Leslie EM,Deeley RG,Cole SP.Multidrug resistance proteins:role of P-glycoprotein,MRP1,MRP2,and BCRP(ABCG2)in tissue defense.Toxicol Appl Pharmacol.2005;204(3):216-37.
12 Hoffmann U,Kroemer HK.The ABC transporters MDR1 and MRP2:multiple functions in disposition of xenobiotics and drug resistance.Drug Metab Rev.2004 Oct;36(3-4):669-701.
1 Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenohabditis elegans[J].Nature,1998.391;806-811.
2 Verma NK,Dey CS.RNA-mediated gene silencing:mechanisms and its therapeutic applications[J].J ClinPharm Ther,2004,29(5):395-404.
3 Bustin SA.Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays.J Mol Endocrinol,2000;25:169-93.
4 Bustin SA.Quantification of mRNA using real-time reverse transcription PCR(RT-PCR):trends and problems.J Mol Endocrinol,2002;29:23-39.
5 Guo JQ,Lin H,Kantarjian H,et al.Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.Leukemia,2002;16:2447-53.
6 Dotsch J,Repp R,Rascher W,et al.Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas.Expert Rev Mol Diagn,2001;1:233-8.
7 Giulietti A,Overbergh L,Valckx D,et al.An overview of real-time quantitative PCR:applications to quantify cytokine gene expression.Methods,2001;25:386-401.
8 Castello R,Estelles A,Vazquez C,et al.Quantitative real-time reverse transcription PCR assay for urokinase plasminogen activator,plasminogen activator inhibitor type 1,and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.Clin Chem,2002,48(8):1288-1295.
9 Cazzaniga G,Rossi V,Biondi A.Mornitoring minimal residualdisease using chromosomal translocations in childhood acute lymphoblastic leukemia.Best Pract Res Clin Haematol,2002;15:21-35.
10 Crimwade D. The significance of minimal residual disease in pationts with t(15;17). Best Pract Res Clin Haematol, 2002;15: 137-158.
11 Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques ,1999 ;26: 112-22,124-5.
12 Elbashir SM. Lendeckel W. Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs [J].Genes Dev. 2001. 15(2): 188-200.
13 Castello R, Estelles A, Vazquez C, et al. Quantitative real-time reverse transcription PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer[J]. Clin Chem , 2002, 48(8): 1288-1295.
14 Fire A, Xu S, Montgomery MK, et al. Potent and specific interference by double-stranded RNA in Caenorhabditis elegants. Nature, 1998, 391(6669),806-811.
15 Michaela Scherr, Michael A. Morgan and Matthial Eder. Gene Silencing mediated by small interfering RNAs in mammalian cells. CurrentMedicinal Chemistry, 2003, 10(3): 245-256.
16 V. Narry Kim. RNA interference in functional genomics and medicine. J Korean Sci, 2003,18(3): 309-318.
17 Lipardi C, Wei Q, Paterson BM. RNAi as random degradative PCR. siRNA primers convent mRNA into dsRNA that are degraded to generate new siRNAs[J]Cell, 2001,107: 297.
18 Ketting RF, Haverkamp TH, VanLuenen HG, et al. Mut-7 of Celegans, required for transposon silencing and RNA interference is a homolog of Wemer syndrome helicase and RNase DE. Cell, 1999, 99: 133.
19 Dzitoyeva S, Dimitrijevic N, Manev H. Intra-abdominal injection of double-staranded RNA into anesthetized adult Drosophila triggers RNA interference in the central nervous system[J]. Mol Psychiatry, 2001, 6(6): 665.
20 Grishok A. Pasquinelli AE. Conte D. et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that Control C. elegans developmental timing[J], Cell, 2001, 106: 23.
21 Lipardi C, Wei Q. Paterson BM . RNAi as random degradative PCR. siRNA prim ers convent mRNA intodsRNA that are degraded to generatenew siRNAs[J]Cell,2001,107(3):297-307.
22 Silen T,Fleenor J,et al.On the roleof RNA amplification in dsRNA-triggered gene silencing[J].Cell,2002,107(4):465-467.
23 Nishikura K.A short primer onRNAi:RNA-directed RNA poly-merase acts as a key catalyst[J].Cell,2001,107(4):415-418.
24 Yukihide T,Phillip DZ。Perspective:machines for RNAi[J].Genes Dev.2005.19(6):517-529.
25 Guangchao Sui,Christina Soohoo,El Bachir Affar,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cell.PANS,2002,99(8):5515-5520.
26 Hiroaki Kawasaki and Kazunari Taira.Short hairpin type of dsRNAs thatare controlled by tRNAval promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells.Nucleic Acids Research,2003,31(2):700-707.
27 Sledz CA,Holko M,de Veer MJ,et al.Activation of the interferon system by short-interfering RNAs.Nature Cell Biol.2003,5:834-9.
28 Bridge AJ,Pebernard S,Ducraux A,et al.Induction of an interferon response by RNAi vectors in maimalian cells.Nature Genet,2003,34:263-4.
29 Jackson AL,Bartz SR,Scheher J,et al.Expression profiling reveals off-target gene regulation by RNAi.Nature Biotechnol,2003,21:635-7.
30 Scacheri PC,Rozenblatt-Rosen O,Caplen NJ,et al.Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.Proc Natl Acad Sci USA,2004,101:1892-7.